CN103781467A - 一种快速溶解药物组合物 - Google Patents
一种快速溶解药物组合物 Download PDFInfo
- Publication number
- CN103781467A CN103781467A CN201280043356.2A CN201280043356A CN103781467A CN 103781467 A CN103781467 A CN 103781467A CN 201280043356 A CN201280043356 A CN 201280043356A CN 103781467 A CN103781467 A CN 103781467A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- active component
- preparation
- compositions
- levan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 55
- AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 claims abstract description 57
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 53
- 229920001202 Inulin Polymers 0.000 claims abstract description 50
- 229940029339 inulin Drugs 0.000 claims abstract description 50
- 239000000203 mixture Substances 0.000 claims description 83
- 238000002360 preparation method Methods 0.000 claims description 62
- 238000000034 method Methods 0.000 claims description 56
- 239000002552 dosage form Substances 0.000 claims description 45
- 239000000758 substrate Substances 0.000 claims description 41
- 210000003296 saliva Anatomy 0.000 claims description 35
- 238000007710 freezing Methods 0.000 claims description 30
- 230000008014 freezing Effects 0.000 claims description 30
- 239000012736 aqueous medium Substances 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 26
- 239000002904 solvent Substances 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 17
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 claims description 12
- 238000004821 distillation Methods 0.000 claims description 12
- 238000004108 freeze drying Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 229960003088 loratadine Drugs 0.000 claims description 9
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical group C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
- 229930195725 Mannitol Natural products 0.000 claims description 8
- 239000000594 mannitol Substances 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- 229960001596 famotidine Drugs 0.000 claims description 7
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical group NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims description 7
- 229960005343 ondansetron Drugs 0.000 claims description 7
- FIEYHAAMDAPVCH-UHFFFAOYSA-N 2-methyl-1h-quinazolin-4-one Chemical group C1=CC=C2NC(C)=NC(=O)C2=C1 FIEYHAAMDAPVCH-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 229960004281 desmopressin Drugs 0.000 claims description 6
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical group C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 claims description 6
- 229960002845 desmopressin acetate Drugs 0.000 claims description 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 5
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims description 5
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 5
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 5
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 5
- 239000007892 solid unit dosage form Substances 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 abstract description 21
- 150000004676 glycans Chemical class 0.000 abstract description 5
- 229920001282 polysaccharide Polymers 0.000 abstract description 5
- 239000005017 polysaccharide Substances 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 description 34
- 239000000047 product Substances 0.000 description 26
- 239000003814 drug Substances 0.000 description 24
- 239000002351 wastewater Substances 0.000 description 20
- 238000004090 dissolution Methods 0.000 description 18
- 210000000214 mouth Anatomy 0.000 description 14
- 241000206672 Gelidium Species 0.000 description 10
- 108010059642 isinglass Proteins 0.000 description 10
- 229910052627 muscovite Inorganic materials 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000006185 dispersion Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229960005127 montelukast Drugs 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 229930091371 Fructose Natural products 0.000 description 6
- 239000005715 Fructose Substances 0.000 description 6
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 6
- 239000004373 Pullulan Substances 0.000 description 6
- 229920001218 Pullulan Polymers 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000004567 concrete Substances 0.000 description 6
- 235000019423 pullulan Nutrition 0.000 description 6
- 238000007789 sealing Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 241000193830 Bacillus <bacterium> Species 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 5
- 239000012876 carrier material Substances 0.000 description 5
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 5
- 239000003246 corticosteroid Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- -1 erithritol Chemical compound 0.000 description 5
- 229920001206 natural gum Polymers 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 4
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 4
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 4
- 241000589232 Gluconobacter oxydans Species 0.000 description 4
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 4
- 241000588653 Neisseria Species 0.000 description 4
- 102400000050 Oxytocin Human genes 0.000 description 4
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 4
- 101800000989 Oxytocin Proteins 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 201000005485 Toxoplasmosis Diseases 0.000 description 4
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 4
- 241000588902 Zymomonas mobilis Species 0.000 description 4
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 4
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 4
- 229960005207 auranofin Drugs 0.000 description 4
- 229960001671 azapropazone Drugs 0.000 description 4
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 4
- 229960004277 benorilate Drugs 0.000 description 4
- FEJKLNWAOXSSNR-UHFFFAOYSA-N benorilate Chemical compound C1=CC(NC(=O)C)=CC=C1OC(=O)C1=CC=CC=C1OC(C)=O FEJKLNWAOXSSNR-UHFFFAOYSA-N 0.000 description 4
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 229960004630 chlorambucil Drugs 0.000 description 4
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 4
- 229960004415 codeine phosphate Drugs 0.000 description 4
- 229960002069 diamorphine Drugs 0.000 description 4
- 229960000616 diflunisal Drugs 0.000 description 4
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 4
- JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 description 4
- 229960004913 dydrogesterone Drugs 0.000 description 4
- ONKUMRGIYFNPJW-KIEAKMPYSA-N ethynodiol diacetate Chemical compound C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 ONKUMRGIYFNPJW-KIEAKMPYSA-N 0.000 description 4
- 229960005293 etodolac Drugs 0.000 description 4
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 4
- 229960005420 etoposide Drugs 0.000 description 4
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 229960001680 ibuprofen Drugs 0.000 description 4
- 229960000905 indomethacin Drugs 0.000 description 4
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 4
- 229960000991 ketoprofen Drugs 0.000 description 4
- 229960004400 levonorgestrel Drugs 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229960003464 mefenamic acid Drugs 0.000 description 4
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 4
- 229960001924 melphalan Drugs 0.000 description 4
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 4
- 229960001428 mercaptopurine Drugs 0.000 description 4
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 4
- 229960004963 mesalazine Drugs 0.000 description 4
- 229960001797 methadone Drugs 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 229960002009 naproxen Drugs 0.000 description 4
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 4
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 4
- 229960001723 oxytocin Drugs 0.000 description 4
- 239000003002 pH adjusting agent Substances 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 229960002702 piroxicam Drugs 0.000 description 4
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 229960005205 prednisolone Drugs 0.000 description 4
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 206010039083 rhinitis Diseases 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 4
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 3
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 241000186044 Actinomyces viscosus Species 0.000 description 3
- 240000004246 Agave americana Species 0.000 description 3
- 229930003347 Atropine Natural products 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 3
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 3
- 244000298479 Cichorium intybus Species 0.000 description 3
- 235000007542 Cichorium intybus Nutrition 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 240000008892 Helianthus tuberosus Species 0.000 description 3
- 235000003230 Helianthus tuberosus Nutrition 0.000 description 3
- 206010021639 Incontinence Diseases 0.000 description 3
- 208000016604 Lyme disease Diseases 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 201000009906 Meningitis Diseases 0.000 description 3
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 3
- 206010039085 Rhinitis allergic Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- 241000589636 Xanthomonas campestris Species 0.000 description 3
- 239000003741 agents affecting lipid metabolism Substances 0.000 description 3
- 201000010105 allergic rhinitis Diseases 0.000 description 3
- 239000002160 alpha blocker Substances 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229940069428 antacid Drugs 0.000 description 3
- 239000003159 antacid agent Substances 0.000 description 3
- 239000004004 anti-anginal agent Substances 0.000 description 3
- 230000002686 anti-diuretic effect Effects 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- 230000002460 anti-migrenic effect Effects 0.000 description 3
- 230000000842 anti-protozoal effect Effects 0.000 description 3
- 230000003356 anti-rheumatic effect Effects 0.000 description 3
- 229940125713 antianxiety drug Drugs 0.000 description 3
- 239000003416 antiarrhythmic agent Substances 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 229940124538 antidiuretic agent Drugs 0.000 description 3
- 229960002708 antigout preparations Drugs 0.000 description 3
- 239000003430 antimalarial agent Substances 0.000 description 3
- 229940034982 antineoplastic agent Drugs 0.000 description 3
- 239000003904 antiprotozoal agent Substances 0.000 description 3
- 239000003435 antirheumatic agent Substances 0.000 description 3
- 229940043671 antithyroid preparations Drugs 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 239000002249 anxiolytic agent Substances 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 229960000396 atropine Drugs 0.000 description 3
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 229960002092 busulfan Drugs 0.000 description 3
- 229960004596 cabergoline Drugs 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 208000024376 chronic urticaria Diseases 0.000 description 3
- 229960003120 clonazepam Drugs 0.000 description 3
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 3
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 239000000850 decongestant Substances 0.000 description 3
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 3
- 229960004192 diphenoxylate Drugs 0.000 description 3
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 229960001971 ebastine Drugs 0.000 description 3
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 238000002657 hormone replacement therapy Methods 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 229960005015 local anesthetics Drugs 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 3
- 201000003152 motion sickness Diseases 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 229940126578 oral vaccine Drugs 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 3
- 229960003981 proparacaine Drugs 0.000 description 3
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 3
- 238000004080 punching Methods 0.000 description 3
- 229960003946 selegiline Drugs 0.000 description 3
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 3
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 3
- 229960001940 sulfasalazine Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229960000580 terconazole Drugs 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 229960004045 tolterodine Drugs 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 3
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 2
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 2
- CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 2
- VXLBSYHAEKDUSU-JXMROGBWSA-N (2e)-2-(fluoromethylidene)-4-(4-fluorophenyl)butan-1-amine Chemical compound NC\C(=C\F)CCC1=CC=C(F)C=C1 VXLBSYHAEKDUSU-JXMROGBWSA-N 0.000 description 2
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 2
- GDFGTRDCCWFXTG-SCTDSRPQSA-N (3r,4ar,10as)-3-(diethylsulfamoylamino)-6-hydroxy-1-propyl-3,4,4a,5,10,10a-hexahydro-2h-benzo[g]quinoline Chemical compound C1=CC=C2C[C@@H]3N(CCC)C[C@H](NS(=O)(=O)N(CC)CC)C[C@H]3CC2=C1O GDFGTRDCCWFXTG-SCTDSRPQSA-N 0.000 description 2
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 2
- FJIKWRGCXUCUIG-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1-methyl-3h-1,4-benzodiazepin-2-one Chemical compound O=C([C@H](O)N=1)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1Cl FJIKWRGCXUCUIG-HNNXBMFYSA-N 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 2
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 description 2
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 2
- RKUNBYITZUJHSG-FXUDXRNXSA-N (S)-atropine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 2
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 2
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 2
- UXAWFWFJXIANHZ-UHFFFAOYSA-N 1-[2-[2-[di(propan-2-yl)amino]ethoxy]phenyl]butan-1-one Chemical compound CCCC(=O)C1=CC=CC=C1OCCN(C(C)C)C(C)C UXAWFWFJXIANHZ-UHFFFAOYSA-N 0.000 description 2
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 2
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 2
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- QNIUOGIMJWORNZ-UHFFFAOYSA-N 2-(diethylamino)ethyl 4-butoxybenzoate Chemical compound CCCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1 QNIUOGIMJWORNZ-UHFFFAOYSA-N 0.000 description 2
- BMDZNGISRKXXIF-UHFFFAOYSA-N 2-(dimethylamino)ethyl 3-amino-4-chlorobenzoate Chemical compound CN(C)CCOC(=O)C1=CC=C(Cl)C(N)=C1 BMDZNGISRKXXIF-UHFFFAOYSA-N 0.000 description 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 2
- XNMYNYSCEJBRPZ-UHFFFAOYSA-N 2-[(3-butyl-1-isoquinolinyl)oxy]-N,N-dimethylethanamine Chemical compound C1=CC=C2C(OCCN(C)C)=NC(CCCC)=CC2=C1 XNMYNYSCEJBRPZ-UHFFFAOYSA-N 0.000 description 2
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 2
- OQDPVLVUJFGPGQ-UHFFFAOYSA-N 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidine Chemical compound C=1C=C2OCOC2=CC=1CN(CC1)CCN1C1=NC=CC=N1 OQDPVLVUJFGPGQ-UHFFFAOYSA-N 0.000 description 2
- PYTMYKVIJXPNBD-OQKDUQJOSA-N 2-[4-[(z)-2-chloro-1,2-diphenylethenyl]phenoxy]-n,n-diethylethanamine;hydron;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(/Cl)C1=CC=CC=C1 PYTMYKVIJXPNBD-OQKDUQJOSA-N 0.000 description 2
- FSVJFNAIGNNGKK-UHFFFAOYSA-N 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 description 2
- GKNPSSNBBWDAGH-UHFFFAOYSA-N 2-hydroxy-2,2-diphenylacetic acid (1,1-dimethyl-3-piperidin-1-iumyl) ester Chemical compound C1[N+](C)(C)CCCC1OC(=O)C(O)(C=1C=CC=CC=1)C1=CC=CC=C1 GKNPSSNBBWDAGH-UHFFFAOYSA-N 0.000 description 2
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 2
- PUYOAVGNCWPANW-UHFFFAOYSA-N 2-methylpropyl 4-aminobenzoate Chemical compound CC(C)COC(=O)C1=CC=C(N)C=C1 PUYOAVGNCWPANW-UHFFFAOYSA-N 0.000 description 2
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 2
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 2
- JXZZEXZZKAWDSP-UHFFFAOYSA-N 3-(2-(4-Benzamidopiperid-1-yl)ethyl)indole Chemical compound C1CN(CCC=2C3=CC=CC=C3NC=2)CCC1NC(=O)C1=CC=CC=C1 JXZZEXZZKAWDSP-UHFFFAOYSA-N 0.000 description 2
- FOHHNHSLJDZUGQ-UHFFFAOYSA-N 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)-9-phenanthrenyl]-1-propanol Chemical compound FC(F)(F)C1=CC=C2C(C(O)CCN(CCCC)CCCC)=CC3=C(Cl)C=C(Cl)C=C3C2=C1 FOHHNHSLJDZUGQ-UHFFFAOYSA-N 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- HQFWVSGBVLEQGA-UHFFFAOYSA-N 4-aminobenzoic acid 3-(dibutylamino)propyl ester Chemical compound CCCCN(CCCC)CCCOC(=O)C1=CC=C(N)C=C1 HQFWVSGBVLEQGA-UHFFFAOYSA-N 0.000 description 2
- SODWJACROGQSMM-UHFFFAOYSA-N 5,6,7,8-tetrahydronaphthalen-1-amine Chemical compound C1CCCC2=C1C=CC=C2N SODWJACROGQSMM-UHFFFAOYSA-N 0.000 description 2
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 2
- VCCNKWWXYVWTLT-CYZBKYQRSA-N 7-[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)chromen-4-one Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 VCCNKWWXYVWTLT-CYZBKYQRSA-N 0.000 description 2
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 2
- 241000590020 Achromobacter Species 0.000 description 2
- 208000003200 Adenoma Diseases 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- 244000291564 Allium cepa Species 0.000 description 2
- 240000002234 Allium sativum Species 0.000 description 2
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010001935 American trypanosomiasis Diseases 0.000 description 2
- OVCDSSHSILBFBN-UHFFFAOYSA-N Amodiaquine Chemical compound C1=C(O)C(CN(CC)CC)=CC(NC=2C3=CC=C(Cl)C=C3N=CC=2)=C1 OVCDSSHSILBFBN-UHFFFAOYSA-N 0.000 description 2
- 229930183010 Amphotericin Natural products 0.000 description 2
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 2
- 244000144730 Amygdalus persica Species 0.000 description 2
- 108010087765 Antipain Proteins 0.000 description 2
- 240000005528 Arctium lappa Species 0.000 description 2
- 235000003130 Arctium lappa Nutrition 0.000 description 2
- QTGIAADRBBLJGA-UHFFFAOYSA-N Articaine Chemical compound CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC QTGIAADRBBLJGA-UHFFFAOYSA-N 0.000 description 2
- 241000228212 Aspergillus Species 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 201000008283 Atrophic Rhinitis Diseases 0.000 description 2
- 241000194108 Bacillus licheniformis Species 0.000 description 2
- 241000194107 Bacillus megaterium Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- CULUWZNBISUWAS-UHFFFAOYSA-N Benznidazole Chemical compound [O-][N+](=O)C1=NC=CN1CC(=O)NCC1=CC=CC=C1 CULUWZNBISUWAS-UHFFFAOYSA-N 0.000 description 2
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- VMIYHDSEFNYJSL-UHFFFAOYSA-N Bromazepam Chemical compound C12=CC(Br)=CC=C2NC(=O)CN=C1C1=CC=CC=N1 VMIYHDSEFNYJSL-UHFFFAOYSA-N 0.000 description 2
- RKLNONIVDFXQRX-UHFFFAOYSA-N Bromperidol Chemical compound C1CC(O)(C=2C=CC(Br)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 RKLNONIVDFXQRX-UHFFFAOYSA-N 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- UMSGKTJDUHERQW-UHFFFAOYSA-N Brotizolam Chemical compound C1=2C=C(Br)SC=2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl UMSGKTJDUHERQW-UHFFFAOYSA-N 0.000 description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241001532039 Camassia Species 0.000 description 2
- 241000589876 Campylobacter Species 0.000 description 2
- 208000024699 Chagas disease Diseases 0.000 description 2
- 201000009182 Chikungunya Diseases 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 2
- PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 description 2
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 2
- CHBRHODLKOZEPZ-UHFFFAOYSA-N Clotiazepam Chemical compound S1C(CC)=CC2=C1N(C)C(=O)CN=C2C1=CC=CC=C1Cl CHBRHODLKOZEPZ-UHFFFAOYSA-N 0.000 description 2
- 208000003495 Coccidiosis Diseases 0.000 description 2
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 description 2
- 208000001490 Dengue Diseases 0.000 description 2
- 206010012310 Dengue fever Diseases 0.000 description 2
- MDNWOSOZYLHTCG-UHFFFAOYSA-N Dichlorophen Chemical compound OC1=CC=C(Cl)C=C1CC1=CC(Cl)=CC=C1O MDNWOSOZYLHTCG-UHFFFAOYSA-N 0.000 description 2
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 2
- ZEFNOZRLAWVAQF-UHFFFAOYSA-N Dinitolmide Chemical compound CC1=C(C(N)=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O ZEFNOZRLAWVAQF-UHFFFAOYSA-N 0.000 description 2
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 2
- 108010061435 Enalapril Proteins 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 2
- 208000008967 Enuresis Diseases 0.000 description 2
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- 201000000297 Erysipelas Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 2
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 2
- 208000004729 Feline Leukemia Diseases 0.000 description 2
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 2
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 2
- WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 241000606790 Haemophilus Species 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- DKLKMKYDWHYZTD-UHFFFAOYSA-N Hexylcaine Chemical compound C=1C=CC=CC=1C(=O)OC(C)CNC1CCCCC1 DKLKMKYDWHYZTD-UHFFFAOYSA-N 0.000 description 2
- 229940122236 Histamine receptor antagonist Drugs 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 244000116484 Inula helenium Species 0.000 description 2
- 235000002598 Inula helenium Nutrition 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 206010023076 Isosporiasis Diseases 0.000 description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
- 241000710842 Japanese encephalitis virus Species 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- JAYAGJDXJIDEKI-UHFFFAOYSA-N Lanatoside C Natural products CC1OC(OC2CC3C(C4C(C5(CCC(C5(C)C(O)C4)C=4COC(=O)C=4)O)CC3)(C)CC2)CC(O)C1OC(OC1C)CC(O)C1OC(OC1C)CC(OC(C)=O)C1OC1OC(CO)C(O)C(O)C1O JAYAGJDXJIDEKI-UHFFFAOYSA-N 0.000 description 2
- JAYAGJDXJIDEKI-PTGWOZRBSA-N Lanatoside C Chemical compound O([C@H]1[C@@H](OC(C)=O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@@H]1C[C@@H]2[C@]([C@@H]3[C@H]([C@]4(CC[C@@H]([C@@]4(C)[C@H](O)C3)C=3COC(=O)C=3)O)CC2)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JAYAGJDXJIDEKI-PTGWOZRBSA-N 0.000 description 2
- 208000004023 Legionellosis Diseases 0.000 description 2
- 208000035353 Legionnaires disease Diseases 0.000 description 2
- 208000007764 Legionnaires' Disease Diseases 0.000 description 2
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- IPWKIXLWTCNBKN-UHFFFAOYSA-N Madelen Chemical compound CC1=NC=C([N+]([O-])=O)N1CC(O)CCl IPWKIXLWTCNBKN-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- QSLMDECMDJKHMQ-UHFFFAOYSA-N Maprotiline Chemical compound C12=CC=CC=C2C2(CCCNC)C3=CC=CC=C3C1CC2 QSLMDECMDJKHMQ-UHFFFAOYSA-N 0.000 description 2
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 2
- YLCXGBZIZBEVPZ-UHFFFAOYSA-N Medazepam Chemical compound C12=CC(Cl)=CC=C2N(C)CCN=C1C1=CC=CC=C1 YLCXGBZIZBEVPZ-UHFFFAOYSA-N 0.000 description 2
- WESWYMRNZNDGBX-YLCXCWDSSA-N Mefloquine hydrochloride Chemical compound Cl.C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 WESWYMRNZNDGBX-YLCXCWDSSA-N 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 2
- JEYCTXHKTXCGPB-UHFFFAOYSA-N Methaqualone Chemical compound CC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C JEYCTXHKTXCGPB-UHFFFAOYSA-N 0.000 description 2
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 2
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 239000004368 Modified starch Substances 0.000 description 2
- 241000588655 Moraxella catarrhalis Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- YUGZHQHSNYIFLG-UHFFFAOYSA-N N-phenylcarbamic acid [2-[anilino(oxo)methoxy]-3-(1-piperidinyl)propyl] ester Chemical compound C1CCCCN1CC(OC(=O)NC=1C=CC=CC=1)COC(=O)NC1=CC=CC=C1 YUGZHQHSNYIFLG-UHFFFAOYSA-N 0.000 description 2
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 2
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 2
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000003450 Neurogenic Diabetes Insipidus Diseases 0.000 description 2
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 2
- YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- APTGJECXMIKIET-WOSSHHRXSA-N Norethindrone enanthate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)CCCCCC)[C@@]1(C)CC2 APTGJECXMIKIET-WOSSHHRXSA-N 0.000 description 2
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 2
- 241000714209 Norwalk virus Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 2
- 206010033078 Otitis media Diseases 0.000 description 2
- FTLDJPRFCGDUFH-UHFFFAOYSA-N Oxethazaine Chemical compound C=1C=CC=CC=1CC(C)(C)N(C)C(=O)CN(CCO)CC(=O)N(C)C(C)(C)CC1=CC=CC=C1 FTLDJPRFCGDUFH-UHFFFAOYSA-N 0.000 description 2
- 244000215747 Pachyrhizus erosus Species 0.000 description 2
- 235000001591 Pachyrhizus erosus Nutrition 0.000 description 2
- 235000018669 Pachyrhizus tuberosus Nutrition 0.000 description 2
- 241000178960 Paenibacillus macerans Species 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 2
- VQASKUSHBVDKGU-UHFFFAOYSA-N Paramethadione Chemical compound CCC1(C)OC(=O)N(C)C1=O VQASKUSHBVDKGU-UHFFFAOYSA-N 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 2
- 201000005702 Pertussis Diseases 0.000 description 2
- VBCPVIWPDJVHAN-UHFFFAOYSA-N Phenoxybenzamine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C[NH+](CCCl)C(C)COC1=CC=CC=C1 VBCPVIWPDJVHAN-UHFFFAOYSA-N 0.000 description 2
- WLWFNJKHKGIJNW-UHFFFAOYSA-N Phensuximide Chemical compound O=C1N(C)C(=O)CC1C1=CC=CC=C1 WLWFNJKHKGIJNW-UHFFFAOYSA-N 0.000 description 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 2
- JPYHHZQJCSQRJY-UHFFFAOYSA-N Phloroglucinol Natural products CCC=CCC=CCC=CCC=CCCCCC(=O)C1=C(O)C=C(O)C=C1O JPYHHZQJCSQRJY-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010035718 Pneumonia legionella Diseases 0.000 description 2
- 208000000474 Poliomyelitis Diseases 0.000 description 2
- 244000134540 Polymnia sonchifolia Species 0.000 description 2
- 235000003406 Polymnia sonchifolia Nutrition 0.000 description 2
- CAJIGINSTLKQMM-UHFFFAOYSA-N Propoxycaine Chemical compound CCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC CAJIGINSTLKQMM-UHFFFAOYSA-N 0.000 description 2
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 241000589615 Pseudomonas syringae Species 0.000 description 2
- AQXXZDYPVDOQEE-MXDQRGINSA-N Pyrantel pamoate Chemical compound CN1CCCN=C1\C=C\C1=CC=CS1.C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 AQXXZDYPVDOQEE-MXDQRGINSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 description 2
- 206010037742 Rabies Diseases 0.000 description 2
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 2
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 206010039088 Rhinitis atrophic Diseases 0.000 description 2
- 241000158504 Rhodococcus hoagii Species 0.000 description 2
- 241000606701 Rickettsia Species 0.000 description 2
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 2
- 241000710942 Ross River virus Species 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- 229920000377 Sinistrin Polymers 0.000 description 2
- 239000004187 Spiramycin Substances 0.000 description 2
- LKAJKIOFIWVMDJ-IYRCEVNGSA-N Stanazolol Chemical compound C([C@@H]1CC[C@H]2[C@@H]3CC[C@@]([C@]3(CC[C@@H]2[C@@]1(C)C1)C)(O)C)C2=C1C=NN2 LKAJKIOFIWVMDJ-IYRCEVNGSA-N 0.000 description 2
- FDMBBCOBEAVDAO-UHFFFAOYSA-N Stovaine Chemical compound CN(C)CC(C)(CC)OC(=O)C1=CC=CC=C1 FDMBBCOBEAVDAO-UHFFFAOYSA-N 0.000 description 2
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 2
- HMHVCUVYZFYAJI-UHFFFAOYSA-N Sultiame Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1S(=O)(=O)CCCC1 HMHVCUVYZFYAJI-UHFFFAOYSA-N 0.000 description 2
- 240000001949 Taraxacum officinale Species 0.000 description 2
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 2
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- JOAHPSVPXZTVEP-YXJHDRRASA-N Terguride Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NC(=O)N(CC)CC)=C3C2=CNC3=C1 JOAHPSVPXZTVEP-YXJHDRRASA-N 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 2
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 2
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 2
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical compound C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 2
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 2
- 241000223109 Trypanosoma cruzi Species 0.000 description 2
- 208000037386 Typhoid Diseases 0.000 description 2
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 2
- 241000607598 Vibrio Species 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 208000003152 Yellow Fever Diseases 0.000 description 2
- 241000607734 Yersinia <bacteria> Species 0.000 description 2
- 241000588901 Zymomonas Species 0.000 description 2
- RVCSYOQWLPPAOA-CVPHZBIISA-M [(5s)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate;chloride Chemical compound [Cl-].[N+]12([C@H]3CCC2CC(C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 RVCSYOQWLPPAOA-CVPHZBIISA-M 0.000 description 2
- 229960002122 acebutolol Drugs 0.000 description 2
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 2
- 229960004420 aceclofenac Drugs 0.000 description 2
- 229960004892 acemetacin Drugs 0.000 description 2
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 2
- 229960002054 acenocoumarol Drugs 0.000 description 2
- VABCILAOYCMVPS-UHFFFAOYSA-N acenocoumarol Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=C([N+]([O-])=O)C=C1 VABCILAOYCMVPS-UHFFFAOYSA-N 0.000 description 2
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 2
- 229960000571 acetazolamide Drugs 0.000 description 2
- 229960001466 acetohexamide Drugs 0.000 description 2
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
- 229960003792 acrivastine Drugs 0.000 description 2
- PWACSDKDOHSSQD-IUTFFREVSA-N acrivastine Chemical compound C1=CC(C)=CC=C1C(\C=1N=C(\C=C\C(O)=O)C=CC=1)=C/CN1CCCC1 PWACSDKDOHSSQD-IUTFFREVSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 229960002669 albendazole Drugs 0.000 description 2
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960004685 aloxiprin Drugs 0.000 description 2
- MANKSFVECICGLK-UHFFFAOYSA-K aloxiprin Chemical compound [OH-].[Al+3].CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O MANKSFVECICGLK-UHFFFAOYSA-K 0.000 description 2
- 229960004538 alprazolam Drugs 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 229960002213 alprenolol Drugs 0.000 description 2
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 2
- 229960001280 amantadine hydrochloride Drugs 0.000 description 2
- WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 description 2
- 229960002576 amiloride Drugs 0.000 description 2
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 2
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 2
- 229960003437 aminoglutethimide Drugs 0.000 description 2
- 229960005260 amiodarone Drugs 0.000 description 2
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 2
- 229960001301 amobarbital Drugs 0.000 description 2
- 229960001444 amodiaquine Drugs 0.000 description 2
- 229960002519 amoxapine Drugs 0.000 description 2
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 2
- 229940009444 amphotericin Drugs 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960002105 amrinone Drugs 0.000 description 2
- RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 description 2
- 229960001220 amsacrine Drugs 0.000 description 2
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 2
- 229960000806 amylocaine Drugs 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 230000003555 analeptic effect Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 description 2
- 230000001458 anti-acid effect Effects 0.000 description 2
- 229940127003 anti-diabetic drug Drugs 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000000078 anti-malarial effect Effects 0.000 description 2
- 229940035678 anti-parkinson drug Drugs 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 239000003160 antidiuretic agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 2
- 239000003200 antithyroid agent Substances 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 229960004046 apomorphine Drugs 0.000 description 2
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 2
- 229960003831 articaine Drugs 0.000 description 2
- 229960004754 astemizole Drugs 0.000 description 2
- GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 2
- 229960002274 atenolol Drugs 0.000 description 2
- 229960002319 barbital Drugs 0.000 description 2
- 229960005200 beclamide Drugs 0.000 description 2
- JPYQFYIEOUVJDU-UHFFFAOYSA-N beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 description 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 2
- 229950001742 benethamine penicillin Drugs 0.000 description 2
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 description 2
- 229960004916 benidipine Drugs 0.000 description 2
- AIZFEOPQVZBNGH-UHFFFAOYSA-N bentazepam Chemical compound C1=2C=3CCCCC=3SC=2NC(=O)CN=C1C1=CC=CC=C1 AIZFEOPQVZBNGH-UHFFFAOYSA-N 0.000 description 2
- 229950001957 bentazepam Drugs 0.000 description 2
- 229960004001 benznidazole Drugs 0.000 description 2
- 229960005274 benzocaine Drugs 0.000 description 2
- VXJABHHJLXLNMP-UHFFFAOYSA-N benzoic acid [2-methyl-2-(propylamino)propyl] ester Chemical compound CCCNC(C)(C)COC(=O)C1=CC=CC=C1 VXJABHHJLXLNMP-UHFFFAOYSA-N 0.000 description 2
- JAQPGQYDZJZOIN-LQDWTQKMSA-N benzylpenicillin benethamine Chemical compound C=1C=CC=CC=1C[NH2+]CCC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 JAQPGQYDZJZOIN-LQDWTQKMSA-N 0.000 description 2
- 229960000254 bephenium Drugs 0.000 description 2
- AVWWVJUMXRXPNF-UHFFFAOYSA-N bephenium Chemical compound C=1C=CC=CC=1C[N+](C)(C)CCOC1=CC=CC=C1 AVWWVJUMXRXPNF-UHFFFAOYSA-N 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 229960002537 betamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
- 229960000516 bezafibrate Drugs 0.000 description 2
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 2
- YSXKPIUOCJLQIE-UHFFFAOYSA-N biperiden Chemical compound C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 description 2
- 229960003003 biperiden Drugs 0.000 description 2
- 229960000503 bisacodyl Drugs 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 229960002729 bromazepam Drugs 0.000 description 2
- NOJMTMIRQRDZMT-GSPXQYRGSA-N bromocriptine methanesulfonate Chemical compound CS(O)(=O)=O.C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 NOJMTMIRQRDZMT-GSPXQYRGSA-N 0.000 description 2
- 229960004037 bromperidol Drugs 0.000 description 2
- 229960003051 brotizolam Drugs 0.000 description 2
- ZFPNOTAGQWNERF-UHFFFAOYSA-N bucricaine Chemical compound C1=CC=C2C(NCCCC)=C(CCCC3)C3=NC2=C1 ZFPNOTAGQWNERF-UHFFFAOYSA-N 0.000 description 2
- 229950006909 bucricaine Drugs 0.000 description 2
- 229960004436 budesonide Drugs 0.000 description 2
- 229960004064 bumetanide Drugs 0.000 description 2
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 2
- 229960003150 bupivacaine Drugs 0.000 description 2
- 229960003369 butacaine Drugs 0.000 description 2
- 229960001290 butanilicaine Drugs 0.000 description 2
- VWYQKFLLGRBICZ-UHFFFAOYSA-N butanilicaine Chemical compound CCCCNCC(=O)NC1=C(C)C=CC=C1Cl VWYQKFLLGRBICZ-UHFFFAOYSA-N 0.000 description 2
- STDBAQMTJLUMFW-UHFFFAOYSA-N butobarbital Chemical compound CCCCC1(CC)C(=O)NC(=O)NC1=O STDBAQMTJLUMFW-UHFFFAOYSA-N 0.000 description 2
- HOZOZZFCZRXYEK-GSWUYBTGSA-M butylscopolamine bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CCCC)=CC=CC=C1 HOZOZZFCZRXYEK-GSWUYBTGSA-M 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 229960003475 cambendazole Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960000623 carbamazepine Drugs 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- 229960001704 carbimazole Drugs 0.000 description 2
- CFOYWRHIYXMDOT-UHFFFAOYSA-N carbimazole Chemical compound CCOC(=O)N1C=CN(C)C1=S CFOYWRHIYXMDOT-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229960001658 carbromal Drugs 0.000 description 2
- OPNPQXLQERQBBV-UHFFFAOYSA-N carbromal Chemical compound CCC(Br)(CC)C(=O)NC(N)=O OPNPQXLQERQBBV-UHFFFAOYSA-N 0.000 description 2
- 208000028235 central diabetes insipidus Diseases 0.000 description 2
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229960004782 chlordiazepoxide Drugs 0.000 description 2
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 2
- 229960002023 chloroprocaine Drugs 0.000 description 2
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 2
- 229960003677 chloroquine Drugs 0.000 description 2
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
- 229960002155 chlorothiazide Drugs 0.000 description 2
- 229960003291 chlorphenamine Drugs 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 229960001761 chlorpropamide Drugs 0.000 description 2
- 229960001523 chlortalidone Drugs 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 206010072757 chronic spontaneous urticaria Diseases 0.000 description 2
- VKQDZNZTPGLGFD-UHFFFAOYSA-N ciclazindol Chemical compound C12=NCCCN2C2=CC=CC=C2C1(O)C1=CC=CC(Cl)=C1 VKQDZNZTPGLGFD-UHFFFAOYSA-N 0.000 description 2
- 229950009468 ciclazindol Drugs 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 229960001380 cimetidine Drugs 0.000 description 2
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 2
- 229960001747 cinchocaine Drugs 0.000 description 2
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 2
- 229960000876 cinnarizine Drugs 0.000 description 2
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 2
- 229960004621 cinoxacin Drugs 0.000 description 2
- VDUWPHTZYNWKRN-UHFFFAOYSA-N cinoxacin Chemical compound C1=C2N(CC)N=C(C(O)=O)C(=O)C2=CC2=C1OCO2 VDUWPHTZYNWKRN-UHFFFAOYSA-N 0.000 description 2
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 2
- 229960005132 cisapride Drugs 0.000 description 2
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 2
- 229960002626 clarithromycin Drugs 0.000 description 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 2
- 229950005728 clibucaine Drugs 0.000 description 2
- 229960005228 clioquinol Drugs 0.000 description 2
- 229960001403 clobazam Drugs 0.000 description 2
- CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 description 2
- 229960004287 clofazimine Drugs 0.000 description 2
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 description 2
- 229960001214 clofibrate Drugs 0.000 description 2
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 2
- 229960004414 clomethiazole Drugs 0.000 description 2
- 229940046989 clomiphene citrate Drugs 0.000 description 2
- 229950005888 clormecaine Drugs 0.000 description 2
- 229960003622 clotiazepam Drugs 0.000 description 2
- 229960004022 clotrimazole Drugs 0.000 description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 2
- 229960003326 cloxacillin Drugs 0.000 description 2
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 2
- 229960004170 clozapine Drugs 0.000 description 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 230000002254 contraceptive effect Effects 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 229960003290 cortisone acetate Drugs 0.000 description 2
- 229960003564 cyclizine Drugs 0.000 description 2
- UVKZSORBKUEBAZ-UHFFFAOYSA-N cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 description 2
- YLRNESBGEGGQBK-UHFFFAOYSA-N cyclomethycaine Chemical compound CC1CCCCN1CCCOC(=O)C(C=C1)=CC=C1OC1CCCCC1 YLRNESBGEGGQBK-UHFFFAOYSA-N 0.000 description 2
- 229960004741 cyclomethycaine Drugs 0.000 description 2
- 229960001140 cyproheptadine Drugs 0.000 description 2
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
- 229960003901 dacarbazine Drugs 0.000 description 2
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 2
- 229960000766 danazol Drugs 0.000 description 2
- QERUYFVNIOLCHV-UHFFFAOYSA-N darodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC2=NON=C12 QERUYFVNIOLCHV-UHFFFAOYSA-N 0.000 description 2
- 229950009702 darodipine Drugs 0.000 description 2
- JHAYEQICABJSTP-UHFFFAOYSA-N decoquinate Chemical compound N1C=C(C(=O)OCC)C(=O)C2=C1C=C(OCC)C(OCCCCCCCCCC)=C2 JHAYEQICABJSTP-UHFFFAOYSA-N 0.000 description 2
- 229960001878 decoquinate Drugs 0.000 description 2
- 229960002398 demeclocycline Drugs 0.000 description 2
- 208000025729 dengue disease Diseases 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 229960004976 desogestrel Drugs 0.000 description 2
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960004597 dexfenfluramine Drugs 0.000 description 2
- 201000010064 diabetes insipidus Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 229960004042 diazoxide Drugs 0.000 description 2
- 229960003887 dichlorophen Drugs 0.000 description 2
- 229960001193 diclofenac sodium Drugs 0.000 description 2
- 229960001912 dicoumarol Drugs 0.000 description 2
- DOBMPNYZJYQDGZ-UHFFFAOYSA-N dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 description 2
- 229960002656 didanosine Drugs 0.000 description 2
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 2
- 229960005493 difenoxin Drugs 0.000 description 2
- UFIVBRCCIRTJTN-UHFFFAOYSA-N difenoxin Chemical compound C1CC(C(=O)O)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 UFIVBRCCIRTJTN-UHFFFAOYSA-N 0.000 description 2
- 229960000648 digitoxin Drugs 0.000 description 2
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
- 229960000920 dihydrocodeine Drugs 0.000 description 2
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 2
- 229960000807 dihydroergotamine mesylate Drugs 0.000 description 2
- ADYPXRFPBQGGAH-UMYZUSPBSA-N dihydroergotamine mesylate Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 ADYPXRFPBQGGAH-UMYZUSPBSA-N 0.000 description 2
- 229960001111 diloxanide Drugs 0.000 description 2
- BDYYDXJSHYEDGB-UHFFFAOYSA-N diloxanide furoate Chemical compound C1=CC(N(C(=O)C(Cl)Cl)C)=CC=C1OC(=O)C1=CC=CO1 BDYYDXJSHYEDGB-UHFFFAOYSA-N 0.000 description 2
- 229960004993 dimenhydrinate Drugs 0.000 description 2
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 2
- 229960003934 dinitolmide Drugs 0.000 description 2
- 229960002228 diperodon Drugs 0.000 description 2
- 229960000520 diphenhydramine Drugs 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 2
- 229960002768 dipyridamole Drugs 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 229960001066 disopyramide Drugs 0.000 description 2
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 229960003413 dolasetron Drugs 0.000 description 2
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 2
- 229960001253 domperidone Drugs 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- 229960000394 droperidol Drugs 0.000 description 2
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 2
- 229960000385 dyclonine Drugs 0.000 description 2
- BZEWSEKUUPWQDQ-UHFFFAOYSA-N dyclonine Chemical compound C1=CC(OCCCC)=CC=C1C(=O)CCN1CCCCC1 BZEWSEKUUPWQDQ-UHFFFAOYSA-N 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 229960003645 econazole nitrate Drugs 0.000 description 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 2
- 229960000873 enalapril Drugs 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 229960000972 enoximone Drugs 0.000 description 2
- ZJKNESGOIKRXQY-UHFFFAOYSA-N enoximone Chemical compound C1=CC(SC)=CC=C1C(=O)C1=C(C)NC(=O)N1 ZJKNESGOIKRXQY-UHFFFAOYSA-N 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- 229960001903 ergotamine tartrate Drugs 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 229960004770 esomeprazole Drugs 0.000 description 2
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229960001842 estramustine Drugs 0.000 description 2
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 2
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 2
- 229960003199 etacrynic acid Drugs 0.000 description 2
- GXRZIMHKGDIBEW-UHFFFAOYSA-N ethinamate Chemical compound NC(=O)OC1(C#C)CCCCC1 GXRZIMHKGDIBEW-UHFFFAOYSA-N 0.000 description 2
- 229960002209 ethinamate Drugs 0.000 description 2
- 229960002568 ethinylestradiol Drugs 0.000 description 2
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 2
- 229960002001 ethionamide Drugs 0.000 description 2
- 229960003533 ethotoin Drugs 0.000 description 2
- SZQIFWWUIBRPBZ-UHFFFAOYSA-N ethotoin Chemical compound O=C1N(CC)C(=O)NC1C1=CC=CC=C1 SZQIFWWUIBRPBZ-UHFFFAOYSA-N 0.000 description 2
- 229940012028 ethynodiol diacetate Drugs 0.000 description 2
- 229960003976 etidocaine Drugs 0.000 description 2
- 229960000218 etynodiol Drugs 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 229960004396 famciclovir Drugs 0.000 description 2
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 2
- 229960003580 felodipine Drugs 0.000 description 2
- 229960001395 fenbufen Drugs 0.000 description 2
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 2
- 229960001582 fenfluramine Drugs 0.000 description 2
- 229960002297 fenofibrate Drugs 0.000 description 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 2
- 229960003592 fexofenadine Drugs 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- 229960003670 flecainide acetate Drugs 0.000 description 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 2
- 229960004413 flucytosine Drugs 0.000 description 2
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229960000326 flunarizine Drugs 0.000 description 2
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 2
- 229960000676 flunisolide Drugs 0.000 description 2
- 229960002200 flunitrazepam Drugs 0.000 description 2
- 229960003973 fluocortolone Drugs 0.000 description 2
- GAKMQHDJQHZUTJ-ULHLPKEOSA-N fluocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O GAKMQHDJQHZUTJ-ULHLPKEOSA-N 0.000 description 2
- 229960003336 fluorocortisol acetate Drugs 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 229960003528 flurazepam Drugs 0.000 description 2
- SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 2
- 229960002390 flurbiprofen Drugs 0.000 description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 2
- 229960000289 fluticasone propionate Drugs 0.000 description 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 2
- 229960000848 foscarnet sodium Drugs 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- 229960003883 furosemide Drugs 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 229960002870 gabapentin Drugs 0.000 description 2
- 235000004611 garlic Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 229960003627 gemfibrozil Drugs 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- 229960000346 gliclazide Drugs 0.000 description 2
- 229960001381 glipizide Drugs 0.000 description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 239000000745 gonadal hormone Substances 0.000 description 2
- 229960003727 granisetron Drugs 0.000 description 2
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 229960002867 griseofulvin Drugs 0.000 description 2
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 2
- 229960002146 guaifenesin Drugs 0.000 description 2
- 229960003050 guanabenz acetate Drugs 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 229960003242 halofantrine Drugs 0.000 description 2
- 229960003878 haloperidol Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 229960005388 hexylcaine Drugs 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 229930005342 hyoscyamine Natural products 0.000 description 2
- 229960003210 hyoscyamine Drugs 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 229960002056 indoramin Drugs 0.000 description 2
- 229940124975 inotropic drug Drugs 0.000 description 2
- 229950008706 isobutamben Drugs 0.000 description 2
- 239000000905 isomalt Substances 0.000 description 2
- 235000010439 isomalt Nutrition 0.000 description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 2
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 2
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 2
- 229960003827 isosorbide mononitrate Drugs 0.000 description 2
- 229960004427 isradipine Drugs 0.000 description 2
- 229960004130 itraconazole Drugs 0.000 description 2
- 229960002418 ivermectin Drugs 0.000 description 2
- 229950001903 ketocaine Drugs 0.000 description 2
- 229960004125 ketoconazole Drugs 0.000 description 2
- 229960001632 labetalol Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960002614 lanatoside c Drugs 0.000 description 2
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 2
- 229950005862 lazabemide Drugs 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- CVQFAMQDTWVJSV-BAXNFHPCSA-N lisuride maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 CVQFAMQDTWVJSV-BAXNFHPCSA-N 0.000 description 2
- 229960002247 lomustine Drugs 0.000 description 2
- 229960001571 loperamide Drugs 0.000 description 2
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 2
- PGYPOBZJRVSMDS-UHFFFAOYSA-N loperamide hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 PGYPOBZJRVSMDS-UHFFFAOYSA-N 0.000 description 2
- 229960002983 loperamide hydrochloride Drugs 0.000 description 2
- 229960004391 lorazepam Drugs 0.000 description 2
- 229960004033 lormetazepam Drugs 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 229960004090 maprotiline Drugs 0.000 description 2
- 229960000299 mazindol Drugs 0.000 description 2
- 229960003439 mebendazole Drugs 0.000 description 2
- BAXLBXFAUKGCDY-UHFFFAOYSA-N mebendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CC=C1 BAXLBXFAUKGCDY-UHFFFAOYSA-N 0.000 description 2
- 229960003803 meclofenamic acid Drugs 0.000 description 2
- 229960002225 medazepam Drugs 0.000 description 2
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 2
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 2
- 229960001962 mefloquine Drugs 0.000 description 2
- 229960003869 mepenzolate bromide Drugs 0.000 description 2
- 229960000906 mephenytoin Drugs 0.000 description 2
- GMHKMTDVRCWUDX-UHFFFAOYSA-N mephenytoin Chemical compound C=1C=CC=CC=1C1(CC)NC(=O)N(C)C1=O GMHKMTDVRCWUDX-UHFFFAOYSA-N 0.000 description 2
- ALARQZQTBTVLJV-UHFFFAOYSA-N mephobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)N(C)C1=O ALARQZQTBTVLJV-UHFFFAOYSA-N 0.000 description 2
- 229960002409 mepivacaine Drugs 0.000 description 2
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 2
- 229960004815 meprobamate Drugs 0.000 description 2
- 229950007594 meprylcaine Drugs 0.000 description 2
- JLICHNCFTLFZJN-HNNXBMFYSA-N meptazinol Chemical compound C=1C=CC(O)=CC=1[C@@]1(CC)CCCCN(C)C1 JLICHNCFTLFZJN-HNNXBMFYSA-N 0.000 description 2
- 229960000365 meptazinol Drugs 0.000 description 2
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 2
- 229960001390 mestranol Drugs 0.000 description 2
- 229960004650 metergoline Drugs 0.000 description 2
- WZHJKEUHNJHDLS-QTGUNEKASA-N metergoline Chemical compound C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4N(C)C=C(C=34)C2)C1)C)NC(=O)OCC1=CC=CC=C1 WZHJKEUHNJHDLS-QTGUNEKASA-N 0.000 description 2
- 229960002803 methaqualone Drugs 0.000 description 2
- 229960004584 methylprednisolone Drugs 0.000 description 2
- 229960001566 methyltestosterone Drugs 0.000 description 2
- 229960003746 metildigoxin Drugs 0.000 description 2
- IYJMSDVSVHDVGT-PEQKVOOWSA-N metildigoxin Chemical compound O1[C@H](C)[C@@H](OC)[C@@H](O)C[C@@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O IYJMSDVSVHDVGT-PEQKVOOWSA-N 0.000 description 2
- 229960004503 metoclopramide Drugs 0.000 description 2
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 2
- 229960002817 metolazone Drugs 0.000 description 2
- AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 description 2
- BQDBKDMTIJBJLA-UHFFFAOYSA-N metopimazine Chemical compound C12=CC(S(=O)(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCC(C(N)=O)CC1 BQDBKDMTIJBJLA-UHFFFAOYSA-N 0.000 description 2
- 229960000767 metopimazine Drugs 0.000 description 2
- 229960002237 metoprolol Drugs 0.000 description 2
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 229960003955 mianserin Drugs 0.000 description 2
- 229960002509 miconazole Drugs 0.000 description 2
- 229960003793 midazolam Drugs 0.000 description 2
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 2
- 229960003632 minoxidil Drugs 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 229960000350 mitotane Drugs 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 229950010854 mofegiline Drugs 0.000 description 2
- 239000003149 muscarinic antagonist Substances 0.000 description 2
- BZRYYBWNOUALTQ-HOTGVXAUSA-N myrtecaine Chemical compound CCN(CC)CCOCCC1=CC[C@@H]2C(C)(C)[C@H]1C2 BZRYYBWNOUALTQ-HOTGVXAUSA-N 0.000 description 2
- 229960000739 myrtecaine Drugs 0.000 description 2
- GDDYCOSWVJRUHM-UHFFFAOYSA-N n-(2,4-dichlorophenyl)-3-piperidin-1-ylbutanamide Chemical compound C1CCCCN1C(C)CC(=O)NC1=CC=C(Cl)C=C1Cl GDDYCOSWVJRUHM-UHFFFAOYSA-N 0.000 description 2
- JZXRLKWWVNUZRB-UHFFFAOYSA-N n-(2-aminoethyl)-5-chloropyridine-2-carboxamide Chemical compound NCCNC(=O)C1=CC=C(Cl)C=N1 JZXRLKWWVNUZRB-UHFFFAOYSA-N 0.000 description 2
- UJCARUGFZOJPMI-UHFFFAOYSA-N n-(2-methoxy-4,6-dimethylphenyl)-3-(2-methylpiperidin-1-yl)propanamide Chemical compound COC1=CC(C)=CC(C)=C1NC(=O)CCN1C(C)CCCC1 UJCARUGFZOJPMI-UHFFFAOYSA-N 0.000 description 2
- 229960004270 nabumetone Drugs 0.000 description 2
- 229960004255 nadolol Drugs 0.000 description 2
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 2
- 229960000805 nalbuphine Drugs 0.000 description 2
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 2
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 2
- 229960003255 natamycin Drugs 0.000 description 2
- 239000004311 natamycin Substances 0.000 description 2
- 235000010298 natamycin Nutrition 0.000 description 2
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 2
- JCSREICEMHWFAY-HUUCEWRRSA-N naxagolide Chemical compound C1=C(O)C=C2[C@H]3OCCN(CCC)[C@@H]3CCC2=C1 JCSREICEMHWFAY-HUUCEWRRSA-N 0.000 description 2
- 229950005651 naxagolide Drugs 0.000 description 2
- 201000005119 neurohypophyseal diabetes insipidus Diseases 0.000 description 2
- 230000002232 neuromuscular Effects 0.000 description 2
- 229960001783 nicardipine Drugs 0.000 description 2
- 229960003642 nicergoline Drugs 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 229960000965 nimesulide Drugs 0.000 description 2
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 2
- 229960000715 nimodipine Drugs 0.000 description 2
- 229960004918 nimorazole Drugs 0.000 description 2
- MDJFHRLTPRPZLY-UHFFFAOYSA-N nimorazole Chemical compound [O-][N+](=O)C1=CN=CN1CCN1CCOCC1 MDJFHRLTPRPZLY-UHFFFAOYSA-N 0.000 description 2
- 150000002823 nitrates Chemical class 0.000 description 2
- 229960001454 nitrazepam Drugs 0.000 description 2
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 2
- 229960000564 nitrofurantoin Drugs 0.000 description 2
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 2
- 229960001907 nitrofurazone Drugs 0.000 description 2
- 229960004872 nizatidine Drugs 0.000 description 2
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 2
- 229960002082 norethindrone enanthate Drugs 0.000 description 2
- 229960001158 nortriptyline Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229960000988 nystatin Drugs 0.000 description 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 2
- HKOURKRGAFKVFP-UHFFFAOYSA-N octacaine Chemical compound CCN(CC)C(C)CC(=O)NC1=CC=CC=C1 HKOURKRGAFKVFP-UHFFFAOYSA-N 0.000 description 2
- 229950009333 octacaine Drugs 0.000 description 2
- 229960005017 olanzapine Drugs 0.000 description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 2
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 2
- 229960004110 olsalazine Drugs 0.000 description 2
- 229960002313 ornidazole Drugs 0.000 description 2
- 229960003941 orphenadrine Drugs 0.000 description 2
- QVYRGXJJSLMXQH-UHFFFAOYSA-N orphenadrine Chemical compound C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 QVYRGXJJSLMXQH-UHFFFAOYSA-N 0.000 description 2
- 229960000462 oxamniquine Drugs 0.000 description 2
- XCGYUJZMCCFSRP-UHFFFAOYSA-N oxamniquine Chemical compound OCC1=C([N+]([O-])=O)C=C2NC(CNC(C)C)CCC2=C1 XCGYUJZMCCFSRP-UHFFFAOYSA-N 0.000 description 2
- 229960002739 oxaprozin Drugs 0.000 description 2
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 2
- 229960002698 oxatomide Drugs 0.000 description 2
- BAINIUMDFURPJM-UHFFFAOYSA-N oxatomide Chemical compound O=C1NC2=CC=CC=C2N1CCCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BAINIUMDFURPJM-UHFFFAOYSA-N 0.000 description 2
- 229960004535 oxazepam Drugs 0.000 description 2
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 2
- 229960001816 oxcarbazepine Drugs 0.000 description 2
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 2
- 229960000986 oxetacaine Drugs 0.000 description 2
- BEZZFPOZAYTVHN-UHFFFAOYSA-N oxfendazole Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1S(=O)C1=CC=CC=C1 BEZZFPOZAYTVHN-UHFFFAOYSA-N 0.000 description 2
- 229960004454 oxfendazole Drugs 0.000 description 2
- 229960004570 oxprenolol Drugs 0.000 description 2
- 229960003502 oxybuprocaine Drugs 0.000 description 2
- CMHHMUWAYWTMGS-UHFFFAOYSA-N oxybuprocaine Chemical compound CCCCOC1=CC(C(=O)OCCN(CC)CC)=CC=C1N CMHHMUWAYWTMGS-UHFFFAOYSA-N 0.000 description 2
- 229960000649 oxyphenbutazone Drugs 0.000 description 2
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 229960005019 pantoprazole Drugs 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 229960003274 paramethadione Drugs 0.000 description 2
- OWWVHQUOYSPNNE-UHFFFAOYSA-N parethoxycaine Chemical compound CCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1 OWWVHQUOYSPNNE-UHFFFAOYSA-N 0.000 description 2
- 229960003899 parethoxycaine Drugs 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229960000761 pemoline Drugs 0.000 description 2
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 2
- 229960001639 penicillamine Drugs 0.000 description 2
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 2
- 229960005301 pentazocine Drugs 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 229960004851 pergolide Drugs 0.000 description 2
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 2
- 229960000762 perphenazine Drugs 0.000 description 2
- 229960000280 phenindione Drugs 0.000 description 2
- NFBAXHOPROOJAW-UHFFFAOYSA-N phenindione Chemical compound O=C1C2=CC=CC=C2C(=O)C1C1=CC=CC=C1 NFBAXHOPROOJAW-UHFFFAOYSA-N 0.000 description 2
- 229960002695 phenobarbital Drugs 0.000 description 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
- 229960004227 phensuximide Drugs 0.000 description 2
- 229960002895 phenylbutazone Drugs 0.000 description 2
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 2
- 229960001802 phenylephrine Drugs 0.000 description 2
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 2
- 229960002036 phenytoin Drugs 0.000 description 2
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 description 2
- 229960001553 phloroglucinol Drugs 0.000 description 2
- 229960002808 pholcodine Drugs 0.000 description 2
- GPFAJKDEDBRFOS-FKQDBXSBSA-N pholcodine Chemical compound O([C@@H]1[C@]23CCN([C@H](C4)[C@@H]3C=C[C@@H]1O)C)C1=C2C4=CC=C1OCCN1CCOCC1 GPFAJKDEDBRFOS-FKQDBXSBSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 2
- 229960003634 pimozide Drugs 0.000 description 2
- 229960002508 pindolol Drugs 0.000 description 2
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 2
- 229960004310 piribedil Drugs 0.000 description 2
- 235000021018 plums Nutrition 0.000 description 2
- 238000013001 point bending Methods 0.000 description 2
- 229920000157 polyfructose Polymers 0.000 description 2
- 229960001896 pramocaine Drugs 0.000 description 2
- DQKXQSGTHWVTAD-UHFFFAOYSA-N pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 description 2
- 229960002957 praziquantel Drugs 0.000 description 2
- 229960001289 prazosin Drugs 0.000 description 2
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229960001807 prilocaine Drugs 0.000 description 2
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 2
- 229960002393 primidone Drugs 0.000 description 2
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 2
- 229960003081 probenecid Drugs 0.000 description 2
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 2
- 229960003912 probucol Drugs 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 229960000624 procarbazine Drugs 0.000 description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 2
- 229960003111 prochlorperazine Drugs 0.000 description 2
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 2
- VXPCQISYVPFYRK-UHFFFAOYSA-N profenamine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(CC)CC)C3=CC=CC=C3SC2=C1 VXPCQISYVPFYRK-UHFFFAOYSA-N 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 229960005385 proguanil Drugs 0.000 description 2
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 2
- QZWHWHNCPFEXLL-UHFFFAOYSA-N propan-2-yl n-[2-(1,3-thiazol-4-yl)-3h-benzimidazol-5-yl]carbamate Chemical compound N1C2=CC(NC(=O)OC(C)C)=CC=C2N=C1C1=CSC=N1 QZWHWHNCPFEXLL-UHFFFAOYSA-N 0.000 description 2
- 229950003255 propoxycaine Drugs 0.000 description 2
- 229960002662 propylthiouracil Drugs 0.000 description 2
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 description 2
- 229960002290 pyridostigmine Drugs 0.000 description 2
- 229960000611 pyrimethamine Drugs 0.000 description 2
- WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 2
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 2
- 229960000924 quinagolide Drugs 0.000 description 2
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 2
- 229960000245 rasagiline Drugs 0.000 description 2
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 2
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 2
- 229960003147 reserpine Drugs 0.000 description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- 229960000425 rizatriptan Drugs 0.000 description 2
- TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 description 2
- 229960001879 ropinirole Drugs 0.000 description 2
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 2
- 229960001549 ropivacaine Drugs 0.000 description 2
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 229950009846 scopolamine butylbromide Drugs 0.000 description 2
- 231100000872 sexual dysfunction Toxicity 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- 229960001294 spiramycin Drugs 0.000 description 2
- 235000019372 spiramycin Nutrition 0.000 description 2
- 229930191512 spiramycin Natural products 0.000 description 2
- 229960002256 spironolactone Drugs 0.000 description 2
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 2
- 229960000912 stanozolol Drugs 0.000 description 2
- PBCZLFBEBARBBI-UHFFFAOYSA-N sulfabenzamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC(=O)C1=CC=CC=C1 PBCZLFBEBARBBI-UHFFFAOYSA-N 0.000 description 2
- 229960002673 sulfacetamide Drugs 0.000 description 2
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 2
- 229960004306 sulfadiazine Drugs 0.000 description 2
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 2
- 229960000654 sulfafurazole Drugs 0.000 description 2
- QPPBRPIAZZHUNT-UHFFFAOYSA-N sulfamerazine Chemical compound CC1=CC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 QPPBRPIAZZHUNT-UHFFFAOYSA-N 0.000 description 2
- 229960005404 sulfamethoxazole Drugs 0.000 description 2
- GECHUMIMRBOMGK-UHFFFAOYSA-N sulfapyridine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=N1 GECHUMIMRBOMGK-UHFFFAOYSA-N 0.000 description 2
- 229960002211 sulfapyridine Drugs 0.000 description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
- 229960003329 sulfinpyrazone Drugs 0.000 description 2
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 2
- 229960000894 sulindac Drugs 0.000 description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 2
- 229960002573 sultiame Drugs 0.000 description 2
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 2
- 229960000658 sumatriptan succinate Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- WOXKDUGGOYFFRN-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-IIBYNOLFSA-N 0.000 description 2
- 229960003454 tamoxifen citrate Drugs 0.000 description 2
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 2
- 229960003188 temazepam Drugs 0.000 description 2
- XYKWNRUXCOIMFZ-UHFFFAOYSA-N tepoxalin Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(CCC(=O)N(C)O)=N1 XYKWNRUXCOIMFZ-UHFFFAOYSA-N 0.000 description 2
- 229950009638 tepoxalin Drugs 0.000 description 2
- 229960001693 terazosin Drugs 0.000 description 2
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 2
- 229960002722 terbinafine Drugs 0.000 description 2
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 2
- 229960000351 terfenadine Drugs 0.000 description 2
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 2
- 229960004558 terguride Drugs 0.000 description 2
- 229960005353 testolactone Drugs 0.000 description 2
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 229960002372 tetracaine Drugs 0.000 description 2
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 229960004546 thiabendazole Drugs 0.000 description 2
- 239000004308 thiabendazole Substances 0.000 description 2
- 235000010296 thiabendazole Nutrition 0.000 description 2
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 description 2
- 229960002784 thioridazine Drugs 0.000 description 2
- WZDGZWOAQTVYBX-XOINTXKNSA-N tibolone Chemical compound C([C@@H]12)C[C@]3(C)[C@@](C#C)(O)CC[C@H]3[C@@H]1[C@H](C)CC1=C2CCC(=O)C1 WZDGZWOAQTVYBX-XOINTXKNSA-N 0.000 description 2
- 229960001023 tibolone Drugs 0.000 description 2
- 229960005053 tinidazole Drugs 0.000 description 2
- 229960004214 tioconazole Drugs 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 2
- 229960002277 tolazamide Drugs 0.000 description 2
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 2
- 229960005371 tolbutamide Drugs 0.000 description 2
- UDKICLZCJWQTLS-UHFFFAOYSA-N tolycaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C(=O)OC UDKICLZCJWQTLS-UHFFFAOYSA-N 0.000 description 2
- 229950006609 tolycaine Drugs 0.000 description 2
- 229940125725 tranquilizer Drugs 0.000 description 2
- 239000003204 tranquilizing agent Substances 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 229960003991 trazodone Drugs 0.000 description 2
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- 229960001288 triamterene Drugs 0.000 description 2
- 229960003386 triazolam Drugs 0.000 description 2
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 2
- 229940072040 tricaine Drugs 0.000 description 2
- FQZJYWMRQDKBQN-UHFFFAOYSA-N tricaine methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=CC([NH3+])=C1 FQZJYWMRQDKBQN-UHFFFAOYSA-N 0.000 description 2
- 229960001032 trihexyphenidyl Drugs 0.000 description 2
- GOZBHBFUQHMKQB-UHFFFAOYSA-N trimecaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=C(C)C=C1C GOZBHBFUQHMKQB-UHFFFAOYSA-N 0.000 description 2
- 229950002569 trimecaine Drugs 0.000 description 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 2
- 229960001082 trimethoprim Drugs 0.000 description 2
- 229960002835 trimipramine maleate Drugs 0.000 description 2
- YDGHCKHAXOUQOS-BTJKTKAUSA-N trimipramine maleate Chemical compound [O-]C(=O)\C=C/C([O-])=O.C1CC2=CC=CC=C2[NH+](CC(C[NH+](C)C)C)C2=CC=CC=C21 YDGHCKHAXOUQOS-BTJKTKAUSA-N 0.000 description 2
- 229960001128 triprolidine Drugs 0.000 description 2
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 description 2
- DFHAXXVZCFXGOQ-UHFFFAOYSA-K trisodium phosphonoformate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)P([O-])([O-])=O DFHAXXVZCFXGOQ-UHFFFAOYSA-K 0.000 description 2
- 229960004791 tropicamide Drugs 0.000 description 2
- 229960003688 tropisetron Drugs 0.000 description 2
- UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 description 2
- 229960001530 trospium chloride Drugs 0.000 description 2
- 201000008297 typhoid fever Diseases 0.000 description 2
- 229950005920 vadocaine Drugs 0.000 description 2
- 229960000604 valproic acid Drugs 0.000 description 2
- 229960002381 vardenafil Drugs 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 229960004355 vindesine Drugs 0.000 description 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 229960001475 zolpidem Drugs 0.000 description 2
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 2
- 229960000820 zopiclone Drugs 0.000 description 2
- SVJMILFDDBKCGG-UHFFFAOYSA-N (1e)-1-[amino-(3,4-dichloroanilino)methylidene]-2-propan-2-ylguanidine;hydrochloride Chemical compound Cl.CC(C)N=C(N)\N=C(/N)NC1=CC=C(Cl)C(Cl)=C1 SVJMILFDDBKCGG-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- AKYHKWQPZHDOBW-UHFFFAOYSA-N (5-ethenyl-1-azabicyclo[2.2.2]octan-7-yl)-(6-methoxyquinolin-4-yl)methanol Chemical compound OS(O)(=O)=O.C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 AKYHKWQPZHDOBW-UHFFFAOYSA-N 0.000 description 1
- KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 1
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- HLNSVKSSCLHOSW-TWGQIWQCSA-N (e)-2-(3,4-dimethoxyphenyl)-3-fluoroprop-2-en-1-amine Chemical compound COC1=CC=C(C(\CN)=C/F)C=C1OC HLNSVKSSCLHOSW-TWGQIWQCSA-N 0.000 description 1
- ZHNFLHYOFXQIOW-AHSOWCEXSA-N (s)-[(2r,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;sulfuric acid;dihydrate Chemical compound O.O.OS(O)(=O)=O.C([C@H]([C@H](C1)C=C)C2)CN1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)CN1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 ZHNFLHYOFXQIOW-AHSOWCEXSA-N 0.000 description 1
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 description 1
- GJHKWLSRHNWTAN-UHFFFAOYSA-N 1-ethoxy-4-(4-pentylcyclohexyl)benzene Chemical compound C1CC(CCCCC)CCC1C1=CC=C(OCC)C=C1 GJHKWLSRHNWTAN-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- UIKWDDSLMBHIFT-UVHMKAGCSA-N 2-[4-[(3e)-3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethyl decanoate Chemical compound C1CN(CCOC(=O)CCCCCCCCC)CCN1CC\C=C/1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2\1 UIKWDDSLMBHIFT-UVHMKAGCSA-N 0.000 description 1
- UIKWDDSLMBHIFT-WKIKZPBSSA-N 2-[4-[(3z)-3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethyl decanoate Chemical compound C1CN(CCOC(=O)CCCCCCCCC)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 UIKWDDSLMBHIFT-WKIKZPBSSA-N 0.000 description 1
- NYWSLZMTZNODJM-MCGDBQAWSA-N 2-[5-[(4e,20e)-35-butyl-19-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-10,12,14,16,18,22,26,30,34-nonahydroxy-3,5,21,33-tetramethyl-36-oxo-1-oxacyclohexatriaconta-4,20-dien-2-yl]-4-hydroxyhexyl]guanidine Chemical compound OC1CC(O)CC(O)CC(O)CC(O)CCCC\C(C)=C\C(C)C(C(C)C(O)CCCN=C(N)N)OC(=O)C(CCCC)C(O)C(C)CCC(O)CCCC(O)CCCC(O)\C(C)=C\C1O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 NYWSLZMTZNODJM-MCGDBQAWSA-N 0.000 description 1
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 244000143294 Acrocephalus indicus Species 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 244000087596 Aglaonema pictum Species 0.000 description 1
- 235000005255 Allium cepa Nutrition 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 208000003829 American Hemorrhagic Fever Diseases 0.000 description 1
- 241000294569 Aphelenchoides Species 0.000 description 1
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 201000009695 Argentine hemorrhagic fever Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000000120 Artificial Saliva Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000203233 Aspergillus versicolor Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000589151 Azotobacter Species 0.000 description 1
- 241000589152 Azotobacter chroococcum Species 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 235000000459 Camassia leichtlinii Nutrition 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000459479 Capsula Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 208000004293 Chikungunya Fever Diseases 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 241000724565 Chorella virus Species 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 150000008159 D-fructofuranosides Chemical class 0.000 description 1
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 206010012742 Diarrhoea infectious Diseases 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- 235000005903 Dioscorea Nutrition 0.000 description 1
- 244000281702 Dioscorea villosa Species 0.000 description 1
- 235000000504 Dioscorea villosa Nutrition 0.000 description 1
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 240000006890 Erythroxylum coca Species 0.000 description 1
- 239000001576 FEMA 2977 Substances 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 229920002670 Fructan Polymers 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- YDGKEDTXZDLPSX-UHFFFAOYSA-N IC1=C(O)C=CC(=C1)O.IC1=C(C(=NC2=CC=CC=C12)O)I Chemical compound IC1=C(O)C=CC(=C1)O.IC1=C(C(=NC2=CC=CC=C12)O)I YDGKEDTXZDLPSX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- 241000701460 JC polyomavirus Species 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001293418 Mannheimia haemolytica Species 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- KDLHYOMCWBWLMM-UHFFFAOYSA-N Meclizine hydrochloride Chemical compound O.Cl.Cl.CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 KDLHYOMCWBWLMM-UHFFFAOYSA-N 0.000 description 1
- AJXPJJZHWIXJCJ-UHFFFAOYSA-N Methsuximide Chemical compound O=C1N(C)C(=O)CC1(C)C1=CC=CC=C1 AJXPJJZHWIXJCJ-UHFFFAOYSA-N 0.000 description 1
- LWYXFDXUMVEZKS-ZVFOLQIPSA-N Methysergide maleate Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 LWYXFDXUMVEZKS-ZVFOLQIPSA-N 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- RTBQMJJZWVVTIH-KSBRXOFISA-N N1=CN=CC=C1.C1=CC=CC=C1.C(\C=C/C(=O)O)(=O)O Chemical compound N1=CN=CC=C1.C1=CC=CC=C1.C(\C=C/C(=O)O)(=O)O RTBQMJJZWVVTIH-KSBRXOFISA-N 0.000 description 1
- BEUPRUXLGKNZAM-UHFFFAOYSA-N N1CCNCC1.C(C1=CC=CC=C1)F Chemical compound N1CCNCC1.C(C1=CC=CC=C1)F BEUPRUXLGKNZAM-UHFFFAOYSA-N 0.000 description 1
- 239000000866 Neuromuscular Agent Substances 0.000 description 1
- 208000010359 Newcastle Disease Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- CCOAINFUFGBHBA-UETGHTDLSA-N Oxantel pamoate Chemical compound CN1CCCN=C1\C=C\C1=CC=CC(O)=C1.C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 CCOAINFUFGBHBA-UETGHTDLSA-N 0.000 description 1
- DUDKAZCAISNGQN-UHFFFAOYSA-N Oxyphencyclimine Chemical compound CN1CCCN=C1COC(=O)C(O)(C=1C=CC=CC=1)C1CCCCC1 DUDKAZCAISNGQN-UHFFFAOYSA-N 0.000 description 1
- 241000194105 Paenibacillus polymyxa Species 0.000 description 1
- 241000588912 Pantoea agglomerans Species 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- XPFRXWCVYUEORT-UHFFFAOYSA-N Phenacemide Chemical compound NC(=O)NC(=O)CC1=CC=CC=C1 XPFRXWCVYUEORT-UHFFFAOYSA-N 0.000 description 1
- 241000224565 Phytomonas Species 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 208000035109 Pneumococcal Infections Diseases 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 208000031649 Postoperative Nausea and Vomiting Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- ZGUGWUXLJSTTMA-UHFFFAOYSA-N Promazinum Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZGUGWUXLJSTTMA-UHFFFAOYSA-N 0.000 description 1
- 241000589540 Pseudomonas fluorescens Species 0.000 description 1
- 206010037688 Q fever Diseases 0.000 description 1
- 241000589771 Ralstonia solanacearum Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000203719 Rothia dentocariosa Species 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CRKGMGQUHDNAPB-UHFFFAOYSA-N Sulconazole nitrate Chemical compound O[N+]([O-])=O.C1=CC(Cl)=CC=C1CSC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 CRKGMGQUHDNAPB-UHFFFAOYSA-N 0.000 description 1
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 description 1
- 235000006754 Taraxacum officinale Nutrition 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241001489212 Tuber Species 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 206010052568 Urticaria chronic Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 241000985670 Xanthomonas arboricola pv. pruni Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 1
- JPKKQJKQTPNWTR-KQAYXBCTSA-N [(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2r)-3-hydroxy-2-phenylpropanoate;sulfuric acid;hydrate Chemical compound O.OS(O)(=O)=O.C1([C@H](CO)C(=O)OC2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1.C1([C@H](CO)C(=O)OC2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 JPKKQJKQTPNWTR-KQAYXBCTSA-N 0.000 description 1
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- HSNWZBCBUUSSQD-UHFFFAOYSA-N amyl nitrate Chemical compound CCCCCO[N+]([O-])=O HSNWZBCBUUSSQD-UHFFFAOYSA-N 0.000 description 1
- 229960003116 amyl nitrite Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000001022 anti-muscarinic effect Effects 0.000 description 1
- 230000001062 anti-nausea Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000003208 anti-thyroid effect Effects 0.000 description 1
- 230000002935 anti-urticaria Effects 0.000 description 1
- 229940124345 antianginal agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002589 antineoplastic immunosuppressant Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 229960002028 atropine sulfate Drugs 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960004495 beclometasone Drugs 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 229960003515 bendroflumethiazide Drugs 0.000 description 1
- HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 description 1
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N benzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 229910052599 brucite Inorganic materials 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960003874 butobarbital Drugs 0.000 description 1
- 229960005074 butoconazole Drugs 0.000 description 1
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 description 1
- ZHPWRQIPPNZNML-UHFFFAOYSA-N butoconazole nitrate Chemical compound O[N+]([O-])=O.C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 ZHPWRQIPPNZNML-UHFFFAOYSA-N 0.000 description 1
- 229960002120 butoconazole nitrate Drugs 0.000 description 1
- 229960002463 butoxycaine Drugs 0.000 description 1
- WOINBKOZJUANMQ-UHFFFAOYSA-N butyl 2-aminobenzoate 2-(butylamino)benzoic acid Chemical compound C(CCC)NC1=C(C(=O)O)C=CC=C1.NC1=C(C(=O)OCCCC)C=CC=C1 WOINBKOZJUANMQ-UHFFFAOYSA-N 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- JIVPVXMEBJLZRO-UHFFFAOYSA-N chlorthalidone Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000030949 chronic idiopathic urticaria Diseases 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 235000008957 cocaer Nutrition 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940035811 conjugated estrogen Drugs 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229960001271 desloratadine Drugs 0.000 description 1
- 229960002593 desoximetasone Drugs 0.000 description 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 229960004193 dextropropoxyphene Drugs 0.000 description 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 229960000691 diiodohydroxyquinoline Drugs 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical class [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229960005341 fenoprofen calcium Drugs 0.000 description 1
- VHUXSAWXWSTUOD-UHFFFAOYSA-L fenoprofen calcium (anhydrous) Chemical compound [Ca+2].[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1.[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 VHUXSAWXWSTUOD-UHFFFAOYSA-L 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960005220 fluanisone Drugs 0.000 description 1
- IRYFCWPNDIUQOW-UHFFFAOYSA-N fluanisone Chemical compound COC1=CC=CC=C1N1CCN(CCCC(=O)C=2C=CC(F)=CC=2)CC1 IRYFCWPNDIUQOW-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 229940042988 flupenthixol decanoate Drugs 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 229960001374 fluphenazine decanoate Drugs 0.000 description 1
- VIQCGTZFEYDQMR-UHFFFAOYSA-N fluphenazine decanoate Chemical compound C1CN(CCOC(=O)CCCCCCCCC)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 VIQCGTZFEYDQMR-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960001625 furazolidone Drugs 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940125695 gastrointestinal agent Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000001288 gastroparesis Diseases 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000006910 ice nucleation Effects 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940073062 imuran Drugs 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- UXZFQZANDVDGMM-UHFFFAOYSA-N iodoquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(I)C2=C1 UXZFQZANDVDGMM-UHFFFAOYSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- 230000001983 lactogenic effect Effects 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 229960000418 lisuride maleate Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229960003729 mesuximide Drugs 0.000 description 1
- 229960001703 methylphenobarbital Drugs 0.000 description 1
- 229960004377 methysergide maleate Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229960001951 montelukast sodium Drugs 0.000 description 1
- LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical compound [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 239000003612 morphinomimetic agent Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- CJRQAPHWCGEATR-UHFFFAOYSA-N n-methyl-n-prop-2-ynylbutan-2-amine Chemical compound CCC(C)N(C)CC#C CJRQAPHWCGEATR-UHFFFAOYSA-N 0.000 description 1
- BSNWMBHBPLPDNI-UHFFFAOYSA-N n-methyl-n-prop-2-ynylpentan-2-amine Chemical compound CCCC(C)N(C)CC#C BSNWMBHBPLPDNI-UHFFFAOYSA-N 0.000 description 1
- CSDTZUBPSYWZDX-UHFFFAOYSA-N n-pentyl nitrite Chemical compound CCCCCON=O CSDTZUBPSYWZDX-UHFFFAOYSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 229940087419 nonoxynol-9 Drugs 0.000 description 1
- 229920004918 nonoxynol-9 Polymers 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 229960000535 oxantel Drugs 0.000 description 1
- VRYKTHBAWRESFI-VOTSOKGWSA-N oxantel Chemical compound CN1CCCN=C1\C=C\C1=CC=CC(O)=C1 VRYKTHBAWRESFI-VOTSOKGWSA-N 0.000 description 1
- 229960002369 oxyphencyclimine Drugs 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 229960003396 phenacemide Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- GGYSHFFKUHGBIK-BTJKTKAUSA-N pizotifen maleate Chemical compound OC(=O)\C=C/C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CCC2=C1C=CS2 GGYSHFFKUHGBIK-BTJKTKAUSA-N 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229950010664 primycin Drugs 0.000 description 1
- NYWSLZMTZNODJM-SDUQVVOESA-N primycin Natural products CCCC[C@H]1[C@H](O)[C@H](C)CC[C@@H](O)CCC[C@@H](O)CCC[C@@H](O)C(=C[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)C[C@H](O)C[C@@H](O)C[C@H](O)C[C@H](O)CCCCC(=C[C@@H](C)[C@@H](OC1=O)[C@H](C)[C@H](O)CCCNC(=N)N)C)C NYWSLZMTZNODJM-SDUQVVOESA-N 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960002262 profenamine Drugs 0.000 description 1
- 229960003598 promazine Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 229960004482 quinidine sulfate Drugs 0.000 description 1
- 229960003110 quinine sulfate Drugs 0.000 description 1
- ZHNFLHYOFXQIOW-LPYZJUEESA-N quinine sulfate dihydrate Chemical compound [H+].[H+].O.O.[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 ZHNFLHYOFXQIOW-LPYZJUEESA-N 0.000 description 1
- 229960005038 quinisocaine Drugs 0.000 description 1
- 239000002684 recombinant hormone Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 230000001523 saccharolytic effect Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000934 spermatocidal agent Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 238000005092 sublimation method Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 229960002607 sulconazole Drugs 0.000 description 1
- 229960004718 sulconazole nitrate Drugs 0.000 description 1
- 229960004730 sulfabenzamide Drugs 0.000 description 1
- 229960002597 sulfamerazine Drugs 0.000 description 1
- 229960004940 sulpiride Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- 229960002613 tamsulosin Drugs 0.000 description 1
- ZZIZZTHXZRDOFM-XFULWGLBSA-N tamsulosin hydrochloride Chemical compound [H+].[Cl-].CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-XFULWGLBSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000003856 thermoforming Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960003904 triflupromazine Drugs 0.000 description 1
- XSCGXQMFQXDFCW-UHFFFAOYSA-N triflupromazine Chemical compound C1=C(C(F)(F)F)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 XSCGXQMFQXDFCW-UHFFFAOYSA-N 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/502—Gums
- A23V2250/5046—Fructan
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/502—Gums
- A23V2250/5062—Inulin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/502—Gums
- A23V2250/5068—Levan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
本发明涉及一种药物组合物,该药物组合物包含携带药学活性成分的开放式基质网络,其中所述开放式基质网络包含果聚糖和菊糖这两种多糖。
Description
发明领域
本发明涉及快速溶解药物组合物、制备它们的方法以及它们在哺乳动物特别是人的疾病的治疗和预防中的用途。
发明背景
被设计成在口腔中释放活性成分的快速溶解药物剂型是熟知的并且可以用来递送宽范围的药物(Critical Reviews in Therapeutic Drug CarrierSystems,21(6):433-475(2004);Seager H.(1998),J.Phar.Pharmacol50:375-382;Bandari等(2008年1月),Asian Journal of Pharmaceutics2-11)。
在快速溶解剂型中,药物可以物理地被俘获在由例如甘露糖醇和鱼明胶(EP1501534;EP1165053)、改性淀粉(US6509040)、与氨基酸结合的普鲁兰(pullulan)(EP1803446)、或与山梨糖醇结合的麦芽糊精(maltodextrin)(US2004/0228919)组成的基质中。药物和载体材料的溶液、混悬液或分散液可以填充到泡罩(blister)空腔中,冷冻,之后冻干。然而,以这种方式生产的剂型大多数易碎且是脆性的,具有有限的物理强度,并且不能承受任何压力。另外,如此生产的剂量单位很难包装和拆开。
本发明提供改善的快速分散剂型。
发明概述
本发明提供新的快速溶解口服药物组合物,其通常为单位剂型,通常为口服冻干物(还称为口服崩解片剂)。本发明的快速溶解剂型一方面具有相对高的抗拉强度(即,在三点弯曲试验中破坏片剂所需的力),在另一方面具有快速崩解/溶出时间。尤其,此相对较高抗拉强度允许更容易地将该组合物从其容器(通常为泡罩包装)取出,而无需崩解。本发明的单位剂型通常可以以类似于传统压缩片剂的方式进行处理,其中仅在接触口腔内的含水液体或唾液后才发生崩解。
在一个实施方案中,本发明提供一种药物组合物,所述药物组合物包含携带药学活性成分的开放式基质网络,其中所述开放式基质网络由果聚糖和菊糖两者构成。
在另一个实施方案中,本发明提供一种药物组合物,所述药物组合物包含携带药学活性成分的基质,所述基质在接触水溶液或唾液后快速崩解,所述基质包含果聚糖和菊糖。
本发明的药物组合物的特征在于,一方面它具有相对较高的抗拉强度,以及另一方面具有在水介质或唾液中的快速溶出。
相对较高的抗拉强度允许以类似于常规压缩片剂的方式处理该组合物,尤其包括从保持它们的包装例如泡罩包装中取出,而没有在手指之间损害该剂型的风险。尽管具有此抗拉强度,但本发明的组合物在接触水介质或唾液时快速崩解,尤其该组合物在口服使用时快速崩解。在水介质中或服用后在口腔中(在那里它接触唾液后崩解)的崩解通常在少于30秒内,并且更通常在少于10秒内,有时少于9、8、7、6、5、4、3、2或甚至1秒。
因此,本发明还提供一种药物组合物,所述药物组合物包含药学活性成分、具有抗拉强度以允许消费者以类似于压缩片剂的方式处理该组合物(通常为单位剂型),本发明的药物组合物通常具有范围在约0.05至1.6N/mm2的抗拉强度和使得所述组合物的至少80%在少于30秒内,有时少于10秒,甚至少于9、8、7、6、5、4、3、2或1秒在水介质或唾液中崩解的快速溶出速率。
本发明的药物组合物可以通过例如在冷冻干燥工艺中从包含在溶液中的活性成分和基质形成剂的液体制剂升华溶剂(例如水)而获得。根据一个实施方案,液体制剂的单位剂量量被引入到凹陷(depression)中,然后进行升华,由此获得(在升华后)单位剂型的药物组合物。所述凹陷可以是开放式泡罩包装的凹陷,并且在升华步骤,以及由此在该凹陷中形成所述组合物的固体单位剂型后,将密封膜或箔置于所述凹陷上以形成密封的泡罩包装。
本发明还提供一种用于制备药物组合物的方法,所述方法包括从包含在溶剂中的药学活性成分和果聚糖和菊糖的液体制剂升华所述溶剂。
本发明还提供一种用于制备药物组合物的方法,所述方法包括(a)制备包含在溶剂中的果聚糖和菊糖和活性成分的溶液;(b)冷冻所述溶液;(c)从所述冷冻的溶液升华所述溶剂,其中由此获得的药物组合物为快速分散剂型,其在接触水溶液或唾液后少于30秒内崩解。
发明详述
本发明提供一种快速溶解(通常是口分散(orodispersible))的药物组合物,其通常以单位剂型制备和提供,通常是口服冻干物,所述药物组合物包含活性成分和一种或多种赋形剂。所述赋形剂(通常是主要基质形成剂)中的至少两种是多糖果聚糖和菊糖。
以下是本专利说明书和权利要求书上下文中使用的一些术语:
术语"活性成分"或"药学活性成分"在本文中可互换地使用。
术语"药物组合物"和"组合物"在本文中可互换地用来指本发明的药物组合物。
术语"单位剂型"或"剂型"在本发明中用来指以用于作为单个剂量给药目标个体的剂量的活性药物成分(API)的量配制的所述组合物。根据活性成分的性质、适应症、疾病阶段和本身已知的各种其他因素,单位剂型可以适应用于一次、两次、三次或任何其他次数的每日给药。
术语"携带"应理解为涵盖活性成分和基质之间的任何形式的相互作用,其允许该基质保持和/或容纳活性成分的量并在基质崩解后将其释放到水介质或唾液。
术语"基质"应理解为是指用于活性成分的固体载体介质。所述基质包括至少两种赋形剂。形成所述基质的赋形剂在本文中有时可以称为"基质形成剂"并且所述试剂中的每一个称为"基质形成剂"。
术语"开放式基质网络"应理解为涵盖整体分散有空隙的水溶性或水分散性载体材料(基质形成剂)的基质。所述基质在接触水溶液或唾液后快速崩解。
在一个实施方案中,果聚糖和菊糖是所述组合物中的基质形成剂。在另一个实施方案中,一种或多种辅助基质形成剂可以存在于所述组合物中。
可用作辅助基质形成剂的糖、糖醇、单糖、二糖、三糖、多糖、蛋白质、氨基酸、树胶等的非限制性实例包括但不限于甘露糖醇,海藻糖,棉子糖,肌醇,普鲁兰,蔗糖,乳糖,右旋糖,赤藓醇,木糖醇,乳糖醇,麦芽糖醇,益寿糖(isomalt),丙氨酸,精氨酸,苏氨酸,甘氨酸,半胱氨酸,丝氨酸,组氨酸,缬氨酸,脯氨酸,赖氨酸,天门冬酰胺,谷氨酰胺,核糖,葡萄糖,半乳糖,果糖,麦芽糖,麦芽三糖,瓜尔胶,黄原胶,黄蓍胶,硅酸镁铝(veegum)等。
一般地,制剂的余量(balance)可以是基质。因此,果聚糖和菊糖基质的百分比可以接近100%。根据本发明可用的辅助基质形成剂的量的范围可以为约0至约90%。
在本发明的一个实施方案中,果聚糖是所述组合物中的主要基质形成剂。在另一个实施方案中,菊糖是所述组合物中的主要基质形成剂。在更另一个实施方案中,所述组合物还包括甘露糖醇或棉子糖或海藻糖或它们的组合作为辅助基质形成剂。
在一个实施方案中,果聚糖和菊糖是构成所述组合物的总重量的10-99.99%的基质形成剂。在另一个实施方案中,果聚糖和菊糖构成所述组合物的总重量的30-85%。在更另一个实施方案中,果聚糖和菊糖构成所述组合物的总重量的40-70%。在更另一个实施方案中,果聚糖和菊糖构成所述组合物的总重量的50-65%。
在其他实施方案中,甘露糖醇或海藻糖或棉子糖或它们的组合用作辅助基质形成剂,其构成所述组合物的总重量的0-89.99%。在一个实施方案中,这些辅助基质形成剂构成所述组合物的总重量的15-50%。在另一个实施方案中,这些辅助基质形成剂构成所述组合物的总重量的25-50%。
因此,本发明的组合物可以是包含果聚糖和菊糖作为主要基质形成剂和甘露糖醇或海藻糖或棉子糖(或它们的组合)作为辅助基质形成剂的组合物,其中果聚糖和菊糖构成10-99.99%(成分的所有%为w/w,表示合并的所述组合物的所有组分的重量中的所述成分的重量),而辅助基质形成剂构成0-89.99%,通常为25-50%。活性成分的含量通常(但不排他地)可以高达整个组合物的90%,通常在0.01-70%的范围,取决于活性成分的性质。在一个实施方案中,活性成分构成所述组合物总重量的0.01-1%。在另一个实施方案中,活性成分构成所述组合物总重量的0.5-2%。在更另一个实施方案中,活性成分构成所述组合物总重量的5-30%。在其他实施方案中,活性成分构成所述组合物总重量的20-40%。在更其他实施方案中,活性成分构成所述组合物总重量的60-90%。
在一个实施方案中,本发明的组合物不包含鱼明胶。在另一个实施方案中,本发明的组合物不包含改性淀粉。在另一个实施方案中,本发明的组合物不包含与氨基酸结合的普鲁兰。在另一个实施方案中,本发明的组合物不包含与山梨糖醇结合的麦芽糊精。
"崩解时间"和"溶出时间"在本文中可互换使用并且应当理解为是指将本发明的组合物在口腔内的水溶液或唾液中溶解或崩解所需的时间。
如本文使用的"口服溶解时间"应理解为是指将本发明的组合物溶解在口腔中所需的时间。
如本文使用的"快速/迅速崩解/溶出"应理解为涵盖在30秒内,通常10秒内以及有时甚至9、8、7、6、5、4、3、2或1秒内,本发明组合物的至少80%,通常所述组合物的90%并且更通常100%在水介质或唾液(在口腔中)的崩解。
如本文使用的水介质的实例是水或缓冲液(例如,磷酸二氢钾,磷酸氢二钾,磷酸氢钠)或如由Morjaria等(May2004),Dissolution Technologies12–15中描述的人工唾液。
如本文使用的唾液是指哺乳动物尤其是人的口腔中的唾液。
如本文使用的"抗拉强度"应理解为破坏片剂所需的力,其通过三点弯曲试验测量,其中所述片剂经受弯曲应力(Mohd等(2002),DrugDevelopment and Industrial Pharmacy28(7):809-813)。
在一个实施方案中,本发明的药物组合物具有在约0.05-1.6N/mm2范围内的抗拉强度。在另一个实施方案中,本发明的药物组合物具有在约0.05-1.4N/mm2范围内的抗拉强度。在更另一个实施方案中,本发明的药物组合物具有在约0.1-0.3N/mm2范围内的抗拉强度。
预期本发明的药物组合物具有使得所述组合物的至少80%在30秒内、通常在10秒内溶解于水介质或唾液中的快速崩解/溶出速率。在一个实施方案中,本发明的药物组合物具有使得所述组合物的至少90%在30秒内、通常在10秒内溶解于水介质或唾液中的快速崩解/溶出速率。
在一个实施方案中,本发明的组合物具有在约0.05-1.6N/mm2范围内的抗拉强度和使得所述组合物的至少80%在30秒内、通常在10秒内溶解在水介质或唾液的快速崩解/溶出速率。
在另一个实施方案中,本发明提供一种药物组合物,所述药物组合物包含药学活性成分、具有范围在约0.05至1.4N/mm2的抗拉强度和使得所述组合物的至少80%在30秒内、通常在10秒内溶解在水介质或唾液的快速崩解/溶出速率。
在另一个实施方案中,本发明提供一种药物组合物,所述药物组合物包含药学活性成分、具有范围在约0.1至0.3N/mm2的抗拉强度和使得所述组合物的至少80%在30秒内、通常在10秒内溶解在水介质或唾液的快速崩解/溶出速率。
在一个实施方案中,本发明的组合物具有在约0.05-1.6N/mm2范围内的抗拉强度和使得所述组合物的至少90%在30秒内、通常在10秒内溶解在水介质或唾液的快速崩解/溶出速率。
在另一个实施方案中,本发明提供一种药物组合物,所述药物组合物包含药学活性成分、具有范围在约0.05至1.4N/mm2的抗拉强度和使得所述组合物的至少90%在30秒内、通常在10秒内溶解在水介质或唾液的快速崩解/溶出速率。
在另一个实施方案中,本发明提供一种药物组合物,所述药物组合物包含药学活性成分、具有范围在约0.1至0.3N/mm2的抗拉强度和使得所述组合物的至少90%在30秒内、通常在10秒内溶解在水介质或唾液的快速崩解/溶出速率。
所述开放式基质网络使得液体能够通过空隙进入所述剂型并渗透通过其内部。通过水介质(如唾液,水等)的渗透将所述剂型的内部和外部的载体材料暴露于水介质或唾液的作用,由此载体材料的网络快速崩解/溶解。
所述开放式基质结构具有多孔性质并且相比于普通固体形状的药物剂型如(制粒的和压缩的)片剂、丸剂、胶囊、栓剂和子宫托,增强所述剂型的崩解。快速崩解导致由该基质携带的活性成分的快速释放。
在本发明中,开放式基质网络的载体材料是与菊糖或其衍生物组合的果聚糖或其衍生物。
果聚糖(也称为leaven,聚果糖(levulosan),多聚果糖(polyfructosan),多果糖(polyfructose)和polylevulan)是果糖C6H12O6的聚合物。果聚糖是果糖环之间具有β-(2->6)键接的多糖,其中数字描述连接的果糖环中的碳原子并且β描述立体化学关系。果聚糖还被描述为果聚糖(fructan),其中D-呋喃果糖苷单体单元之间的主要糖苷键是β-(2->6)。果聚糖通常由微生物制备并且不作为高分子量化合物出现在植物中。一些分子量小于100,000道尔顿的低分子量果聚糖可以出现在草中。
如本文使用的"果聚糖"应理解为涵盖来源于任何一种或多种来源的果聚糖,所述来源例如但不限于印度滑刃线虫(A.indicus),杂色曲霉(A.versicolor),弱氧化醋杆菌(Acetobacter suboxydans),无色杆菌属(Achromobacter spp.),放线菌(Actinomycenes sp.),粘性放线菌(Actinomycesviscosus),产气杆菌(Aerobacter aerogenes),产果聚糖气杆菌(Aerobacterlevanicum),萨氏曲霉(Aspergillus sydowi),褐球固氮菌(Azotobacterchroococcum),多粘杆菌(Bacillus polymyxa),地衣芽孢杆菌(Bacilluslicheniformis),浸麻芽孢杆菌(Bacillus macerans),巨大芽孢杆菌(Bacillusmegatherium),糖化菌(Bacillus mesentericus),枯草杆菌(Bacillus subtilis),痰唾纤小杆菌(Bacillus vulgates),青枯雷尔氏菌(Corynbacteriumlaevaniformans),冰核活性细菌(Erwinia herbicola),氧化葡萄糖酸菌(Gluconobacter oxydans),肠膜明串珠菌(Leuconostoc mesenteroides),粘液牙霉菌(Odontomyces viscosus),玻璃植物杆菌(Phytobacterium vitrosum),桃李植物单胞菌(Phytomonas pruni),萤光假单胞菌(PsuedomonasFluorescens),丁香假单胞菌(Pseudomonas Syringae),栖李假单胞菌(Pseudomonas prunicola),龋齿罗氏菌(Rothis dentocariosa),基利恩沙雷氏菌(Serratia kiliensis),牛链球菌(Steptococcus bovis),变形链球菌(Steptococcus mutans),链球菌属唾液块菌(Steptococcus salivarius),野油菜黄单胞菌(Xanthomonas campestris),桃李黄单胞菌(Xanthomonaspruni),运动发酵单胞菌(Zymomonas mobilis)等。在具体实施方案中,果聚糖获自发酵单胞菌和芽孢杆菌物种。在更具体的实施方案中,果聚糖获自运动发酵单胞菌。
应理解,也可以使用果聚糖的衍生物(例如,如WO98/03184中描述的)代替果聚糖。
菊糖(inulin)是果糖C6H12O6的一种聚合物,通常具有末端葡萄糖。菊糖是果糖环之间具有β-(2->1)键接的多糖,其中数字描述连接的果糖环中的碳原子并且β描述立体化学关系。菊糖由许多类型的植物产生。
如本文使用的,菊糖应理解为涵盖来源于任何来源的菊糖,所述源如但不限于含有高浓度菊糖的植物,其包括但不限于土木香(Elecampane)(Inula helenium);蒲公英(Dandelion)(Taraxacum officinale);山药(Wild Yam)(Dioscorea spp.);菊芋(Jerusalem artichokes)(Helianthus tuberosus);菊苣(Chicory)(Cichorium intybus);豆薯(Jicama)(Pachyrhizus erosus);牛蒡(Burdock)(Arctium lappa);洋葱(Onion)(Allium cepa);大蒜(Garlic)(Alliumsativum);龙舌兰(Agave)(Agave spp.);雪莲果(Yacón)(Smallanthussonchifolius spp.);和卡马夏(Camas)(Camassia spp.)。在一个具体实施方案中,菊糖获自菊苣(Cichorium intybus)。
所述药学活性成分可以涵盖任何药物成分如药物、化合物、肽、多肽、核苷酸等。
可以由本发明的开放式基质网络携带的药物的非限制性实例是镇痛药,α阻滞剂(alpha blockers),抗过敏药,抗哮喘药,(变应性鼻炎,慢性荨麻疹(chronic uticaria)),抗炎药,抗酸药(antacids),抗蠕虫药(anthelmintics),抗心律失常药(anti-arrhythmic agents),抗关节炎药(anti-arthritis),抗菌药,抗焦虑药,抗凝血药(anti-coagulants),抗抑郁药,抗糖尿病药,止泻药(anti-diarrheals),抗利尿药(anti-diuretics),抗癫痫药(anti-epileptics),抗真菌药,抗痛风药(anti-gout),抗高血压药(anti-hypertensive),抗失禁药(anti-incontinence),抗失眠药(anti-insomnia),抗疟药(anti-malarials),抗偏头痛药(anti-migraine),抗毒蕈碱药(anti-muscarinic),抗肿瘤药(anti-neoplastic)和免疫抑制剂(immunosuppressants),抗原生动物药(anti-protozoal),抗风湿药(anti-rheumatics),抗鼻炎药(anti-rhinitis),抗痉挛药(anti-spasmatic),抗甲状腺药(anti-thyroid),抗病毒药(antivirals),抗焦虑剂(anxiolytics),镇静药(sedatives),催眠药(hypnotics)和精神松弛剂(neuroleptics),β-阻滞剂,抗良性过度增生药(anti-benign hyperplasia(BHP)),心肌收缩药(cardiacinotropic),皮质甾类(corticosteroids),止咳药(cough suppressants),细胞毒性剂(cytotoxics),解充血药(decongestants),糖尿病胃潴留(diabetic gastricstasis),利尿药(diuretics),酶类(enzymes),抗震颤麻痹药(anti-parkinsonian),胃肠,组胺受体拮抗剂,绝育药(infertility),子宫内膜异位症(endometriosis),激素替代疗法(hormone replacement therapy),调血脂药(lipid regulating agents),局麻药(local anesthetics),神经肌肉药(neuromuscular agents),硝酸盐类和抗心绞痛药(anti-anginal agents),月经失调(menstrual disorders),晕动病(motion sickness),抗痛素(anti-pain),抗恶心药(anti-nausea),运动障碍(movement disorders),营养剂(nutritionalagents),阿片类止痛剂(opioid analgesics),口服疫苗(oral vaccines),蛋白质类,肽类和重组药物,预防化疗诱发和术后恶心和呕吐质子泵抑制剂,精神分裂症,性激素和避孕药,癫痫发作/惊恐障碍,性功能障碍(男性和女性),杀精子剂(spermicides),兴奋剂排泄功能障碍,兽医药等。
这些药物的具体非限制性实例是:
α阻滞剂:他索罗辛(Tamsulosine)
镇痛药和抗炎药:阿司匹林,阿洛普令(aloxiprin),金诺芬(auranofin),阿扎丙宗(azapropazone),扑炎痛(benorylate),二氟尼柳(diflunisal),依托度酸(etodolac),芬布芬(fenbufen),苯氧布洛芬钙(fenoprofen calcium),氟比洛芬(flurbiprofen),布洛芬(ibuprofen),吲哚美辛(indomethacin),酮洛芬(ketoprofen),甲氯芬那酸(meclofenamic acid),甲芬那酸(mefenamic acid),萘丁美酮(nabumetone),萘普生(naproxen),奥沙普秦(oxaprozin),羟布宗(oxyphenbutazone),保泰松(phenylbutazone),吡罗昔康(piroxicam),舒林酸(sulindac),扑热息痛(paracetamol)。
抗酸药:氢氧化铝,碳酸镁,三硅酸镁,水滑石,二甲硅油。
抗蠕虫药:阿苯达唑(albendazole),羟萘苄芬宁(bepheniumhydroxynaphthoate),坎苯达唑(cambendazole),二氯芬(dichlorophen),伊维菌素(ivermectin),甲苯达唑(mebendazole),奥沙尼喹(oxamniquine),奥芬达唑(oxfendazole),间酚嘧啶(oxantel embonate),吡喹酮(praziquantel),噻嘧啶恩波酸盐(pyrantel embonate),噻苯哒唑(thiabendazole)。
抗过敏药:地氯雷他定(desloratidine),氯雷他定(loratidine),孟鲁司特(Montelukast),孟鲁司特钠(Montelukast sodium),西替利臻(Cetirizin),非索非那定(Fexofenadin),依巴斯汀(Ebastine)。
抗心律失常药:胺碘酮HCl(amiodarone HCl),丙吡胺(disopyramide),氟卡胺乙酸盐(flecainide acetate),硫酸奎尼丁(quinidine sulphate)。
抗细菌药:苯明青霉素(benethamine penicillin),西诺沙星(cinoxacin),环丙沙星HCl(ciprofloxacin HCl),克拉霉素(clarithromycin),氯法齐明(clofazimine),氯唑西林(cloxacillin),地美环素(demeclocycline),多西环素(doxycycline),红霉素(erythromycin),乙硫异烟胺(ethionamide),亚胺培南(imipenem),萘啶酸(nalidixic acid),呋喃妥因(nitrofurantoin),利福平(rifampicin),螺旋霉素(spiramycin),磺胺苯酰(sulphabenzamide),磺胺多辛(sulphadoxine),磺胺甲基嘧啶(sulphamerazine),磺胺醋酰钠(sulphacetamide),磺胺嘧啶(sulphadiazine),磺胺异噁唑(sulphafurazole),磺胺甲噁唑(sulphamethoxazole),磺胺吡啶(sulphapyridine),四环素(tetracycline),甲氧苄啶(trimethoprim)。
抗凝血药:双香豆素(dicoumarol),双嘧达莫(dipyridamole),醋硝香豆素(nicoumalone),苯茚二酮(phenindione)。
抗抑郁药:阿莫沙平(amoxapine),苯嘧吲哚(ciclazindol),马普替林HCl(maprotiline HCl),米安色林HCl(mianserin HCl),去甲替林HCl(nortriptyline HCl),曲唑酮HCl(trazodone HCl),马来酸曲米帕明(trimipramine maleate)。
抗糖尿病药:醋酸己脲(acetohexamide),氯磺丙脲(chlorpropamide),格列本脲(glibenclamide),格列齐特(gliclazide),格列吡嗪(glipizide),妥拉磺脲(tolazamide),甲苯磺丁脲(tolbutamide)。
止泻药:硫酸阿托品(atropine sulphate),磷酸可待因(codeinephosphate),地芬诺酯+阿托品(co-phenotrope),地芬诺辛(difenoxin),盐酸洛哌丁胺(loperamide hydrochloride),柳氮磺吡啶(suphasolazine),美沙拉嗪(mesalazine),奥沙拉秦(olsalazine),皮质甾类(corticosteroids),泼尼松龙(prednisolone)。
抗利尿药:去氨加压素(desmopressin),醋酸去氨加压素。
抗癫痫药:贝克拉胺(beclamide),卡马西平(carbamazepine),氯硝西泮(clonazepam),乙苯妥英(ethotoin),美芬妥英(methoin),甲琥按(methsuximide),甲苯比妥(methylphenobarbitone),奥卡西平(oxcarbazepine),甲乙双酮(paramethadione),苯乙酰脲(phenacemide),苯巴比通(phenobarbitone),苯妥英(phenytoin),苯琥胺(phensuximide),扑米酮(primidone),舒噻美(sulthiame),丙戊酸(valproic acid)。
抗真菌药:两性霉素(amphotericin),硝酸布康唑(butoconazole nitrate),克霉唑(clotrimazole),硝酸益康唑(econazole nitrate),氟康唑(fluconazole),氟胞嘧啶(flucytosine),灰黄霉素(griseofulvin),伊曲康唑(itraconazole),酮康唑(ketoconazole),咪康唑(miconazole),纳他霉素(natamycin),制霉菌素(nystatin),硫康唑(sulconazole nitrate),特比萘芬HCl(terbinafine HCl),特康唑(terconazole),噻康唑(tioconazole),十一碳烯酸(undecenoic acid)。
抗痛风药:别嘌呤醇(allopurinol),丙磺舒(probenecid),磺吡酮(sulphinpyrazone)。
抗高血压药:氨氯地平(amlopidine),贝尼地平(benidipine),达罗地平(darodipine),地尔硫卓HCl(dilitazem HCl),二氮嗪(diazoxide),非洛地平(felodipine),胍那苄醋酸盐(guanabenz acetate),吲哚拉明(indoramin),伊拉地平(isradipine),米诺地尔(minoxidil),尼卡地平HCl(nicardipine HCl),硝苯地平(nifedipine),尼莫地平(nimodipine),酚苄明HCl(phenoxybenzamine HCl),哌唑嗪HCl(prazosin HCl),利血平(reserpine),特拉唑嗪HCl(terazosin HCl)。
抗失眠药:唑吡坦(Zolpidem)。
抗疟疾药:阿莫地喹(amodiaquine),氯喹(chloroquine),氯丙胍HCl(chloroproguanil HCl),卤泛群HCl(halofantrine HCl),甲氟喹HCl(mefloquine HCl),氯胍HCl(proguanil HCl),乙胺嘧啶(pyrimethamine),硫酸奎宁(quinine sulphate)。
抗偏头疼药:利扎曲普坦(rizatriptan),双氢麦角胺甲磺酸盐(dihydroergotamine mesylate),麦角胺酒石酸盐(ergotamine tartrate),马来酸二甲麦角新碱(methysergide maleate),马来酸苯嘧啶(pizotifen maleate),琥珀酸舒马曲坦(sumatriptan succinate),咖啡因(caffeine)。
抗毒蕈碱药:奥昔布林(oxybutinin),托特罗定(tolterodin),阿托品(atropine),苯海索HCl(benzhexol HCl),比哌立登(biperiden),普罗吩胺HCl(ethopropazine HCl),东莨菪碱丁基溴(hyoscine butyl bromide),莨菪碱(hyoscyamine),溴美喷酯(mepenzolate bromide),奥芬那君(orphenadrine),羟苄利明HCl(oxyphencylcimine HCl),托吡卡胺(tropicamide)。
抗肿瘤药和免疫抑制剂:氨鲁米特(aminoglutethimide),安吖啶(amsacrine),咪唑硫嘌呤(azathioprene),白消安(busulphan),苯丁酸氮芥(chlorambucil),环孢素(cyclosporin),达卡巴嗪(dacarbazine),雌氮芥(estramustine),依托泊甙(etoposide),洛莫司汀(lomustine),美法仑(melphalan),巯嘌呤(mercaptopurine),甲氨蝶呤(methotrexate),丝裂霉素(mitomycin),米托坦(mitotane),米妥蒽醌(mitozantrone),丙卡巴肼HCl(procarbazine HCl),枸橼酸他莫昔芬(tamoxifen citrate),睾内酯(testolactone)。
抗原生动物药:苄硝唑(benznidazole),氯碘羟喹(clioquinol),地考喹酯(decoquinate),双碘喹啉(diiodohydroxyquinoline),二氯尼特(diloxanidefurcate),二硝托胺(dinitolmide),呋喃唑酮(furzolidone),甲硝唑(metronidazole),尼莫唑(nimorazole),硝基糠棕(nitrofurazone),奥硝唑(ornidazole),替硝唑(tinidazole)。
抗风湿药:布洛芬(ibuprofen),醋氯芬酸(aceclofenac),阿西美辛(acemetacin),阿扎丙宗(azapropazone),双氯芬酸钠(diclofenac sodium),二氟尼柳(diflunisal),依托度酸(etodolac),酮洛芬(ketoprofen),吲哚美辛(indomethacin),甲芬那酸(mefenamic acid),萘普生(naproxen),吡罗昔康(piroxicam),阿司匹林,扑炎痛(benorylate),金诺芬(auranofin),青霉胺(penicillamine)。
抗鼻炎药、抗荨麻疹药:西替利臻,非索非那定,依巴斯汀,氯雷他定,孟鲁司特
抗痉挛药:间苯三酚脱水物(phloroglucinol anhydre)
抗甲状腺药:卡比马唑(carbimazole),丙硫氧嘧啶(propylthiouracil)。
抗病毒药:阿昔洛韦(acyclovir),盐酸金刚烷胺(amantadinehydrochloride),泛昔洛韦(famciclovir),齐多夫定(zidovadine),去羟肌苷(didanosine),扎昔他宾(zalcitabine),膦甲酸钠(foscarnet sodium)。
抗焦虑药、镇静药、安眠药和精神松弛剂:阿普唑仑(alprazolam),异戊巴比妥(amylobarbitone),巴比妥(barbitone),苯他西泮(bentazepam),溴西泮(bromazepam),溴哌利多(bromperidol),溴替唑仑(brotizolam),正丁巴比妥(butobarbitone),卡溴脲(carbromal),氯氮卓(chlordiazepoxide),氯苯那敏(Chlorpheniramine),氯美噻唑(chlormethiazole),氯丙嗪(chlorpromazine),氯巴占(clobazam),氯硝西泮(clonazepan),氯噻西泮(clotiazepam),氯氮平(clozapine),地西泮(diazepam),氟哌利多(droperidol),炔己蚁胺(ethinamate),氟阿尼酮(flunanisone),氟硝西泮(flunitrazepam),氟丙嗪(fluopromazine),三氟噻吨癸酸酯(flupenthixol decanoate),癸氟奋乃静(fluphenazine decanoate),氟西泮(flurazepam),氟哌啶醇(haloperidol),劳拉西泮(lorazepam),氯甲西泮(lormetazepam),美达西泮(medazepam),甲丙氨酯(meprobamate),甲喹酮(methaqualone),咪达唑仑(midazolam),硝西泮(nitrazepam),奥沙西泮(oxazepam),戊巴比妥(pentobarbitone),奋乃静(perphenazine)去氧肾上腺素(phenylephrine),匹莫齐特(pimozide),丙氯拉嗪(prochlorperazine),假麻黄碱HCl(pseudoephedrine HCL),舒必利(sulpride),替马西泮(temazepam),硫利达嗪(thioridazine),三唑仑(triazolam),佐匹克隆(zopiclone)。
β-阻滞剂:醋丁洛尔(acebutolol),阿普洛尔(alprenolol),阿替洛尔atenolol),拉贝洛尔(labetalol),美托洛尔(metoprolol),纳多洛尔(nadolol),氧烯洛尔(oxprenolol),吲哚洛尔(pindolol),心得安(propanolol)。
心肌收缩药:氨力农(amrinone),洋地黄毒甙(digitoxin),地高辛(digoxin),依诺昔酮(enoximone),毛花苷C(lanatoside C),甲地高辛(medigoxin)。
皮质甾类:倍氯米松(beclomethasone),倍他米松(betamethasone),布地奈德(budesonide),醋酸可的松(cortisone acetate),脱氧米塞松(desoxymethasone),地塞米松(dexamethasone),醋酸氟氢可的松(fludrocortisone acetate),氟尼缩松(flunisolide),氟可龙(flucortolone),丙酸氟替卡松(fluticasone propionate),氢化可的松(hydrocortisone),甲泼尼龙(methylprednisolone),泼尼松龙(prednisolone),泼尼松(prednisone),曲安西龙(triamcinolone)。
镇咳药:磷酸可待因(codeine phosphate),右美沙芬(dexomethorphan),愈创甘油醚(guaifenesin),福尔可定(pholcodine),二醋吗啡(diamorphine),美沙酮(methadone)。
细胞毒性剂:异环磷酰胺(ifosfamide),苯丁酸氮芥(chlorambucil),美法仑(melphalan),白消安,细胞毒性抗体,多柔比星(doxorubicin),表柔比星(epirubicin),普利霉素(plicamycin),博来霉素(bleomycin),甲氨蝶呤(methotrexate),阿糖胞苷(cytarabine),氟达拉滨(fludarabine),吉西他滨(gencitabine),氟尿嘧啶(fluorouracil),巯嘌呤(mercaptopurine),硫鸟嘌呤(thioguanine),长春新碱(vincristine),长春碱(vinblastine),长春地辛(vindesine),依托泊甙(etoposide)。
解充血药:盐酸伪麻黄碱(pseudoephedrine hydrochloride)。
利尿药:乙酰唑胺(acetazolamide),阿米洛利(amiloride),苄氟嗪(bendrofluazide),布美他尼(bumetanide),氯噻嗪(chlorothiazide),氯噻酮(chlorthalidone),依他尼酸(ethacrynic acid),呋塞米(frusemide),美托拉宗(metolazone),螺内酯(spironolactone),氨苯蝶啶(triamterene)。
酶:胰酶(pancreatin),胃蛋白酶(pepsin),脂肪酶。
癫痫:加巴喷丁(Gabapentin)
抗震颤麻痹药:甲磺酸溴隐亭(bromocriptine mesylate),马来酸麦角乙脲(lysuride maleate),司立吉林(selegiline),对氟司立吉林(para-fluoroselegiline),拉扎贝胺(lazabemide),雷沙吉兰(rasagiline),2-BUMP[N-(2-丁基)-N-甲基炔丙胺],M-2-PP[N-甲基-N-(2-戊基)-炔丙胺],MDL-72145[β-(氟亚甲基)-3,4-二甲氧基-苯乙胺],莫非吉兰(mofegiline),阿扑吗啡(apomorphine),N-丙基去甲阿扑啡(N-propylnoraporphine),卡麦角林(cabergoline),甲麦角林(metergoline),那高利特(naxagolide),培高利特(pergolide),吡贝地尔(piribedil),罗匹尼罗(ropinirole),特麦角脲(terguride),喹高利特(quinagolide)。
胃肠病用药:比沙可啶(bisacodyl),西咪替丁(cimetidine),西沙必利(cisapride),地芬诺酯HCl(diphenoxylate HCl),多潘立酮(domperidone),甲氧氯普胺(metoclopramide),法莫替丁(famotidine),洛哌丁胺(loperamide),美沙拉嗪(mesalazine),尼扎替丁(nizatidine),艾美拉唑(esomeprazole),美托哌丙嗪(metopimazine),泮托拉唑(pantoprazole),昂丹司琼HCl(ondansetron HCl),格拉司琼(Granisetron),托烷司琼(tropisetron),多拉司琼(dolasetron),雷尼替丁HCl(ranitidine HCl),柳氮磺吡啶(sulphasalazine),兰索拉唑(Lanzoprazole),
组胺受体拮抗剂:阿伐斯汀(acrivastine),阿司咪唑(astemizole),桂利嗪(cinnarizine),赛克力嗪(cyclizine),赛庚啶HCl(cyproheptadine HCl),茶苯海明(dimenhydrinate),氟桂利嗪HCl(flunarizine HCl),氯雷他定,美克洛嗪HCl(meclozine HCl),奥沙米特(oxatomide),特非那定(terfenadine),曲普利啶(triprolidine)。
激素替代疗法:地屈孕酮(dydrogesterone)
高血压:依那普利(Enalapril)
泌乳:催产素(Oxytocin),催产素激动剂
脂质调节剂:苯扎贝特(bezafibrate),氯贝丁酯(clofibrate),非诺贝特(fenofibrate),吉非贝齐(gemfibrozil),普罗布可(probucol)。
局麻药:丁卡因(amethocaine),阿米卡因(amylocaine),苯佐卡因(benzocaine),丁吖卡因(bucricaine),布比卡因(bupivacaine),布他卡因(butacaine),布坦卡因(butanilicaine),丁托西卡因(butoxycaine),氨基苯甲酸丁酯(butyl aminobenzoate),卡替卡因(carticaine),氯普鲁卡因(chloroprocaine),辛可卡因(cinchocaine),氯丁卡因(clibucaine),氯美卡因(clormecaine),古柯(coca),可卡因(cocaine),环美卡因(cyclomethycaine),二甲异喹(dimethisoquin),地哌冬(diperodon),达克罗宁(dyclocaine),氯乙烷,对哌啶并乙酰基氨基苯甲酸乙酯(ethylp-piperidinoacetylaminobenzoate),依替卡因(etidocaine),海克卡因(hexylcaine),氨苯异丁酯(isobutamben),凯托卡因(ketocaine),利诺卡因(lignocaine),甲哌卡因(mepivacaine),美普卡因(meprylcaine),麦替卡因(myrtecaine),奥他卡因(octacaine),奥昔卡因(oxethazaine),奥布卡因(oxybuprocaine),对乙氧卡因(parethoxycaine),普拉卡因(pramoxine),丙胺卡因(prilocaine),普鲁卡因(procaine),丙美卡因(propranocaine),丙氧卡因(propoxycaine),丙美卡因(proxymetacaine),罗哌卡因(ropivacaine),托利卡因(tolycaine),三卡因(tricaine),三甲卡因(trimecaine),伐多卡因(vadocaine)。
晕动病:苯海拉明(diphenhydramine)
神经肌肉药:吡啶斯的明(pyridostigmine)。
硝酸盐类和其他抗心绞痛药:亚硝酸异戊酯(amyl nitrate),三硝酸甘油酯(glyceryl trinitrate),硝酸异山梨酯(isosorbide dinitrate),单硝酸异山梨酯(isosorbide mononitrate),四硝酸五赤藓醇酯。
营养剂:β胡萝卜素(betacarotene),维生素,如维生素A、维生素B2、维生素D、维生素E、维生素K、矿物质。
阿片类镇痛药:可待因(codeine),右丙氧芬(dextropropyoxyphene),二醋吗啡(diamorphine),双氢可待因(dihydrocodeine),美普他酚(meptazinol),美沙酮(methadone),吗啡(morphine),纳布啡(nalbuphine),喷他佐辛(pentazocine)。
口服疫苗:用于防止或减少疾病的症状,所述疾病如流感、肺结核(Tuberculosis),脑膜炎(Meningitis),肝炎(Hepatitis),百日咳(WhoopingCough),小儿麻痹症(Polio),破伤风(Tetanus),白喉(Diphtheria),疟疾(Malaria),霍乱(Cholera),疱疹(Herpes),伤寒(Typhoid),HIV,AIDS,麻疹(Measles),莱姆病(Lyme disease),旅行者腹泻(Traveller's Diarrhea),甲、乙和丙型肝炎,中耳炎(Otitis Media),登革热(Dengue Fever),狂犬病(Rabies),副流感(Parainfluenza),风疹(Rubella),黄热病(Yellow Fever),痢疾(Dysentery),军团病(Legionnaires Disease),弓形体病(Toxoplasmosis),Q热(Q-Fever),出血热(Haemorrhegic Fever),阿根廷出血热(ArgentinaHaemorrhegic Fever),龋(Caries),Chagas病(Chagas Disease),由大肠杆菌引起的尿道感染,肺炎球菌病(Pneumococcal Disease),腮腺炎(Mumps),切昆贡亚热(Chikungunya),枯草热(Hayfever),哮喘症(Asthma),风湿性关节炎,癌,球虫病(Coccidiosis),新城疫(Newcastle Disease),地方性动物肺炎(Enzootic pneumonia),猫白血病(Feline leukemia),萎缩性鼻炎(Atrophic rhinitis),丹毒(Erysipelas),口蹄疫和猪肺炎,或者用于防止或减少由以下物种引起的疾病的症状:弧菌物种(Vibrio species),沙门菌物种(Salmonella species),博德特菌物种(Bordetella species),嗜血菌物种(Haemophilus species),弓形虫病(Toxoplasmosis gondii),巨细胞病毒(Cytomegalovirus),衣原体物种(Chlamydia species),链球菌物种(Streptococcal species),诺沃克病毒(Norwalk Virus),大肠杆菌(Escherischiacoli),幽门螺杆菌(Helicobacter pylori),轮状病毒(Rotavirus),淋病奈瑟氏菌(Neisseria gonorrhae),奈瑟氏脑膜炎双球菌(Neisseria meningiditis),腺病毒,EB病毒(Epstein Barr Virus),日本脑炎病毒(Japanese Encephalitis Virus),卡氏肺孢子虫(Pneumocystis carini),单纯疱疹(Herpes simplex),梭状芽胞杆菌物种(Clostridia species),呼吸道合胞体病毒(Respiratory SyncytialVirus),克雷伯氏菌物种(Klebsiella species),志贺氏菌物种(Shigellaspecies),铜绿假单胞菌(Pseudomonas aeruginosa),细小病毒(Parvovirus),弯曲菌物种(Campylobacter species),立克次氏体物种(Rickettsia species),水痘带状疱疹(Varicella zoster),耶尔森氏菌物种(Yersinia species),罗斯河病毒(Ross River Virus),JC病毒(J.C.Virus),马红球菌(Rhodococcus equi),粘膜炎莫拉菌(Moraxella catarrhalis),伯氏疏螺旋体(Borrelia burgdorferi)和溶血巴斯德菌(Pasteurella haemolytica)。
排泄功能障碍:坦洛新(Tamsulosine),曲司氯铵(trospium chloride),托特罗定(tolterodine),奥昔布林(oxybutinin)
蛋白质、肽和重组药:重组激素和异激素,重组细胞因子,重组血纤维蛋白溶酶原(recombinant plasminogens),TNF受体融合蛋白,单克隆抗体,核酸,反义寡核苷酸,寡核苷酸,糖蛋白和粘附分子。
兽鼻炎:替泊沙林(Tepoxalin)
性激素和避孕药:柠檬酸氯芪酚胺(clomiphene citrate),达那唑(danazol),去氧孕烯(desogestrel),炔雌醇(ethinyloestradiol),炔诺醇(ethynodiol),双醋炔诺醇(ethynodiol diacetate),左炔诺孕酮(levonorgestrel),醋酸甲羟孕酮(medroxyprogesterone acetate),美雌醇(mestranol),甲睾酮(methyltestosterone),炔诺酮(norethisterone),庚酸炔诺酮(norethisteroneenanthate),炔诺孕酮(norgestrel),雌二醇(estradiol),共轭雌激素类(conjugated estrogens),地屈孕酮(dydrogesterone),孕酮(progesterone),司坦唑醇(stanozolol),己烯雌酚(stilboestrol),睾酮(testosterone),替勃龙(tibolone)。
精神分裂症:奥氮平(Olanzapine),尼麦角林(Nicergoline)
性功能障碍:卡麦角林(Cabergolin),催产素,他达拉非(tadalafil),西地那非(sildenafil),伐地那非(vardenafil)。
杀精子药:壬苯醇醚9(nonoxynol9)。
兴奋剂:安非他命(amphetamine),右旋安非他命(dexamphetamine),右芬氟拉明(dexfenfluramine),芬氟拉明(fenfluramine),马吲哚(mazindol),匹莫林(pemoline)。
在一个具体的非限制性实施方案中,活性成分是醋酸去氨加压素。在此实施方案中,所述剂型可以用于排泄延缓或者治疗或预防失禁、原发性夜间遗尿症(PNE)、夜尿或中枢性尿崩症(central diabetes insipidus)。在一个实施方案中,所述组合物中的醋酸去氨加压素的量构成0.01–2.00%w/w。在另一个实施方案中,所述组合物中的醋酸去氨加压素的量构成0.04–1.00%w/w。
在一个具体的非限制性实施方案中,活性成分是氯雷他定。在此实施方案中,所述剂型可以例如用于减轻过敏性鼻炎和慢性自发性荨麻疹(chronic idiopathic urticaria)的鼻或非鼻症状。在一个实施方案中,所述组合物中的氯雷他定的量构成20-40%w/w。在另一个实施方案中,所述组合物中的氯雷他定的量构成约25-40%w/w。
在一个具体的非限制性实施方案中,活性成分是法莫替丁。在此实施方案中,所述剂型可以例如用于治疗胃食管反流(gastroesophageal reflux)疾病、十二指肠和胃溃疡、病理性高分泌病症(pathological hypersecretorycondition)(例如,佐-埃二氏综合征(Zollinger-Ellison syndrome)和多发性内分泌腺瘤(multiple endocrine adenomas))。在一个实施方案中,所述组合物中的法莫替丁的量构成50-90%w/w。在另一个实施方案中,所述组合物中的法莫替丁的量构成60–90%w/w。
在一个具体的非限制性实施方案中,活性成分是孟鲁司特钠。在此实施方案中,所述剂型可以例如用于预防和慢性治疗哮喘、过敏性鼻炎和运动诱发的支气管收缩(exercise-induced bronchoconstriction)。在一个实施方案中,所述组合物中的孟鲁司特钠的量构成5-40%w/w。在另一个实施方案中,所述组合物中的孟鲁司特钠的量构成5-30%w/w。
在一个具体的非限制性实施方案中,活性成分是昂丹司琼。在此实施方案中,所述剂型可以例如用于预防术后恶心和/或呕吐以及预防恶性和/或与癌化疗和放射疗法相关的。在一个实施方案中,所述组合物中的昂丹司琼的量构成10-30%w/w。在另一个实施方案中,所述组合物中的昂丹司琼的量构成约20%w/w。
本发明的药物剂型在接触流体(水介质或唾液)后崩解,由此释放所述活性成分。
通常,本发明的药物剂型是口分散药物剂型,其在嘴中在30秒内,通常10秒以下崩解。
如本文使用的术语"口分散"应理解为涵盖在(至多)30秒内在嘴中崩解或溶解的固体剂型。在另一个实施方案中,该口分散剂型在10、9、8、7、6、5、4、3、2或甚至1秒内在嘴中分散。
本发明剂型的合适给药途径是口服给药,包括但不限于含服和舌下给药。在一个具体实施方案中,所述剂型舌下给药。本发明的剂型也可以置于舌头上靠着颊或齿龈。
本发明的药物剂型适于将活性成分提供到例如口腔。活性成分可以穿过给药部位处的粘膜而被吸收,所述粘膜例如舌下粘膜,和/或在口服给药的情况下,从口腔(例如穿过颊粘膜和/或齿龈粘膜)和/或胃肠道分布全身。
所述剂型给药的精确剂量和方案必需取决于要实现的疗效并且可以随着特定活性成分、给药途径以及给予药物的个体对象的年龄和状况变化。有时患者可以被指令在单次给药中服用两个或任何其他数量的单位剂型或者有时在单次给药中仅服用单位剂型的一部分如一半或四分之一。
本发明的剂型实现了性能的平衡:抗拉强度、稳定性和快速崩解。它可以通过已知的冻干技术生产。它可以储存(和包装)在泡罩中但由于其抗拉强度,也可以储存和/或包装在瓶中或散装。本发明在单个加工步骤中实现这些结果,而不需要采取多个步骤包括制粒。
除了之前讨论的成分外,所述基质还可以包括其他赋形剂(助剂,辅助试剂)如但不限于填料、基质形成剂、增稠剂(包括但不限于瓜尔胶和黄原胶)、粘合剂、稀释剂、润滑剂、pH调节剂、保护剂、增粘剂、芯吸剂(wickingagents)、非泡腾崩解剂、泡腾崩解剂、表面活性剂、抗氧化剂、润湿剂、着色剂、调味剂、掩味剂、增甜剂、防腐剂等。
在一个实施方案中,本发明的组合物可通过从包含在溶剂中的活性成分、果聚糖、菊糖和任选的辅助基质形成剂的液体制剂升华溶剂获得。通常,该液体制剂被置于例如模具中,以使在升华后,在该模具内通常以剂量单位形成固体组合物。所述模具可以是开放式泡罩包装,由此该固体剂量单位在之后被密封膜或箔密封的该泡罩包装的凹陷中形成。
在一个实施方案中,所述方法包括将单位剂量量的所述制剂引入到开放式泡罩包装的凹陷中;然后升华所述制剂以在所述凹陷内获得固体剂型。
所述升华可以通过冷冻干燥包含在溶剂中的活性成分、果聚糖、菊糖和任选的辅助基质形成剂的制剂进行。在一个实施方案中,溶剂是水。
因此,本发明公开了一种通过冻干活性成分、果聚糖、菊糖和任选的辅助基质形成剂的组合来制备快速分散剂型的方法。该快速分散剂型包含活性成分和载体果聚糖和菊糖以及任选的辅助基质形成剂的网络,该网络已通过从含有活性成分、果聚糖、菊糖和其他任选基质形成剂的液体制剂升华溶剂获得。所述制剂可以是溶液、混悬液或分散液。
通常,制备包含在溶剂中的活性成分、果聚糖、菊糖和任选的辅助基质形成剂的初始制剂,接着进行升华。所述升华可以通过冷冻干燥该制剂进行。
在冷冻干燥程序中,包含在溶剂中的活性成分、果聚糖、菊糖和任何其他任选的基质形成剂的制剂(液体形式)被填充到模具中。每个模具通常包含限定量的这样的溶液,以及限定量的活性成分。模具中的制剂然后被冷冻,例如通过使气态冷却介质在该模具上方通过。在制剂已被冷冻之后,使溶剂从其升华。升华在冷冻干燥机中进行。结果,由此形成任选地连同所述溶液中含有的其他基质形成剂的果聚糖和菊糖的开放式基质网络。
所述制剂在冷冻干燥工艺期间容纳在模具中以产生任何期望形状的固体形式。在冻干之前,该模具可以被冷却和冷冻(例如在快速冷冻管道中或在冷冻干燥器的搁板上),例如使用液氮或固体二氧化碳。在一个实施方案中,冷冻速率为0.1至2℃/分钟。在另一个实施方案中,冷冻速率为0.5至1.5℃/分钟。在更另一个实施方案中,冷冻速率为10至260℃/分钟。在另一个实施方案中,冷冻速率为10至200℃/分钟。在另一个实施方案中,冷冻速率为10至160℃/分钟。
在冻干后,该冷冻干燥的组合物如果需要可以从模具移出或者储存在其内直至后来使用。通常,每个模具被设计成生产组合物的单位剂型。如此获得的组合物在接触流体后在至多30秒内,通常在少于10秒内快速分散和崩解。
所述溶剂通常是水,但可以任选地还包含共溶剂(如醇,例如叔丁醇)以改善该化学品的溶解性。
所述组合物可以包含pH调节剂以将制备所述剂型的溶液的pH调节在2至10,通常为3.5至9.5或4.5至8。柠檬酸、氢氧化钠和碳酸钠可以用作pH调节剂,但也可以使用其他,包括盐酸和苹果酸。非挥发性pH调节剂通过冷冻干燥或其他升华过程不会被除去,所以可能存在于终产物中。
所述模具在其内可以包括一系列的圆筒形或其他形状的凹陷,各个尺寸对应于要形成的剂型的期望尺寸。
在一个实施方案中,所述模具是膜状材料的板材中的凹陷。该膜状材料可以包含超过一个的凹陷。该膜状材料可以类似于在用于包装口服避孕药片剂和相似药物形式的传统泡罩包装中采用的膜状材料。例如,该膜状材料可以由具有通过热成型或冷成型形成的凹陷的热塑性材料制成。聚氯乙烯膜可以用作膜状材料。也可以使用膜状材料的层合体。
实施例
在以下实施例中进一步描述本发明,这些实施例不以任何方式限制所要求保护的发明的范围。
A.实施例中使用的材料提供如下
B.用于制备安慰剂制剂的方法
1)在以200至500转/分钟(rpm)的搅拌下将果聚糖、菊糖和如果存在的其他赋形剂溶解在净化水中。
2)任选地使用柠檬酸溶液或NaOH调节溶液的pH。
3)用净化水补足溶液的终体积。
4)在200至500rpm的搅拌下降所述溶液混合15分钟。
5)将所述溶液按剂量放入所用泡罩板的每个空腔中(通常使用分配移液管)。
6)在-20至-110℃范围内的温度冷冻所填充的泡罩。
7)在冷冻干燥机中冷冻干燥这些泡罩。
8)将包含经干燥的冻干物的泡罩板置于泡罩包装机的冲压载体网上以将这些泡罩板传输通过包装机的密封站(sealing station)。
9)用封盖箔密封这些泡罩并冲压成最终泡罩。
C1.制剂
以下制剂利用以上方法部分"B"中描述的方法制备,通过在步骤6中以0.1–2℃/分钟的速率冷冻这些泡罩。
实施例-1
组分 | 量/单位 | %w/w |
果聚糖(发酵单胞菌 | 18.75mg | 75 |
(Zymomonas spp.)) | ||
菊糖 | 6.25mg | 25 |
净化水 | 适量至250μl | - |
实施例-2
实施例-3
实施例-4
实施例-5
C2.制剂
以下制剂利用上文"B"中描述的方法制备,通过在步骤6中在≤4分钟以20–160℃/分钟的速率冷冻所述泡罩。
实施例-6
实施例-7
实施例-8
实施例-9
组分 | 量/单位 | %w/w |
果聚糖(发酵单胞菌 | 8.75mg | 35 |
(Zymomonas spp.)) | ||
菊糖 | 16.25mg | 65 |
净化水 | 适量至250μl | - |
实施例-10
实施例-11
实施例-12
D.用于制备含有去氨加压素的剂型的方法
1)在200至500rpm的搅拌下将果聚糖、菊糖以及如果存在的其他赋形剂溶解在净化水中;
2)将醋酸去氨加压素溶解在净化水中并加入到步骤1中制备的溶液中。
3)调节溶液的pH。
4)用净化水补足所述溶液的最终体积。
5)在200至500rpm的搅拌下将所述溶液再混合5-15min。
6)将所述溶液按剂量放入所用泡罩板的空腔中(通常使用分配移液器)。
7)在-20至-110℃范围内的温度冷冻所填充的泡罩。
8)在冷冻干燥机中冷冻干燥这些泡罩。
9)将包含经干燥的冻干物的泡罩板置于泡罩包装机的冲压载体网上,以将这些泡罩板传输通过包装机的密封站。
10)用封盖箔密封这些泡罩并冲压成最终泡罩。
E.去氨加压素制剂
以下去氨加压素冻干物制剂利用以上"D"中描述的方法制备,通过在步骤7中以0.1–2℃/分钟或20–160℃/分钟的速率冷冻所述泡罩。
实施例-13
实施例-14
实施例-15
实施例-16
实施例-17
F.用于制备含有孟鲁司特钠的剂型的方法
1)在搅拌下将孟鲁司特溶解在净化水中。
2)在200–500rpm的搅拌下将果聚糖、菊糖和其他赋形剂溶解在步骤1的孟鲁司特溶液中。
3)用净化水补足所述溶液的最终体积。
4)在200至500rpm的搅拌下将所述溶液再混合15min。
5)将所述溶液按剂量放入所用泡罩的每个空腔中。
6)在-20至-110℃范围内的温度冷冻所填充的泡罩。
7)在冷冻干燥机中冷冻干燥这些泡罩。
8)将包含经干燥的冻干物的泡罩板置于泡罩包装机的冲压载体网上,以将这些泡罩板传输通过包装机的密封站。
9)用封盖箔密封这些泡罩并冲压成最终泡罩。
G.孟鲁司特钠制剂
以下孟鲁司特口分散剂型利用以上“F”中描述的方法制备,通过在步骤6中以0.1–2℃/分钟或20–160℃/分钟的速率冷冻所述泡罩。
实施例-18
实施例-19
H.比较例
实施例–20
比较冻干物根据本文以上"B"中描述的方法制备,但使用普鲁兰代替果聚糖和菊糖的组合,并且在步骤6中以20–260℃/分钟的速率在≤4分钟冷冻所述泡罩。
组分 | 量/单位 | %w/w |
普鲁兰 | 25mg | 100 |
净化水 | 适量250μl | - |
实施例–21
比较冻干物根据本文以上"B"中描述的方法制备,但用HPMC代替果聚糖和菊糖的组合,并且在步骤6中以0.1–2℃/分钟的速率冷冻所述泡罩。
组分 | 量/单位 | %w/w |
HPMC | 25mg | 100 |
净化水 | 适量250μl | - |
实施例–22
比较冻干物根据本文以上"B"中描述的方法制备,但使用HPMC代替果聚糖和菊糖的组合,并且在步骤6中以20–160℃/分钟的速率在≤4分钟冷冻所述泡罩。
组分 | 量/单位 | %w/w |
HPMC | 25mg | 100 |
净化水 | 适量250μl | - |
实施例–23
比较冻干物根据本文以上"B"中描述的方法制备,但用甲基纤维素代替果聚糖和菊糖的组合,并且在步骤6中以0.1–2℃/分钟的速率冷冻所述泡罩。
组分 | 量/单位 | %w/w |
甲基纤维素 | 25mg | 100 |
净化水 | 适量250μl | - |
实施例–24
比较冻干物根据本文以上"B"中描述的方法制备,但使用甲基纤维素代替果聚糖和菊糖的组合,并且在步骤6中以20–160℃/分钟的速率在≤4分钟冷冻所述泡罩。
组分 | 量/单位 | %w/w |
甲基纤维素 | 25mg | 100 |
净化水 | 适量250μl | - |
实施例–25
比较冻干物根据本文以上"B"中描述的方法制备,但用黄菁树胶代替果聚糖和菊糖的组合,并且在步骤6中以0.1–2℃/分钟的速率冷冻所述泡罩。
组分 | 量/单位 | %w/w |
黄菁树胶 | 25mg | 100 |
净化水 | 适量250μl | - |
实施例–26
比较冻干物根据本文以上"B"中描述的方法制备,但使用黄菁树胶代替果聚糖和菊糖的组合,并且在步骤6中以20–160℃/分钟的速率在≤4分钟冷冻所述泡罩。
组分 | 量/单位 | %w/w |
黄菁树胶 | 25mg | 100 |
净化水 | 适量250μl | - |
实施例–27
比较冻干物根据本文以上"B"中描述的方法制备,但用鱼明胶代替果聚糖和菊糖的组合,并且在步骤6中以0.1–2℃/分钟的速率冷冻所述泡罩。
组分 | 量/单位 | %w/w |
鱼明胶 | 25mg | 100 |
净化水 | 适量250μl | - |
所获得的冻干物非常脆并且破碎成小片。不能进行进一步的分析。
实施例–28
比较冻干物根据本文以上"B"中描述的方法制备,但使用鱼明胶代替果聚糖和菊糖的组合,并且在步骤6中以20–160℃/分钟的速率在≤4分钟冷冻所述泡罩。
组分 | 量/单位 | %w/w |
鱼明胶 | 25mg | 100 |
净化水 | 适量250μl | - |
实施例–29
比较冻干物根据本文以上"B"中描述的方法制备,但用鱼明胶代替果聚糖和菊糖的组合,并且在步骤6中以0.1–2℃/分钟的速率冷冻所述泡罩。
组分 | 量/单位 | %w/w |
鱼明胶 | 12.5mg | 50 |
甘露糖醇 | 12.5mg | 50 |
净化水 | 适量250μl | - |
实施例–30
比较冻干物根据本文以上"B"中描述的方法制备,但使用鱼明胶代替果聚糖和菊糖的组合,并且在步骤6中以20–160℃/分钟的速率在≤4分钟冷冻所述泡罩。
组分 | 量/单位 | %w/w |
鱼明胶 | 12.5mg | 50 |
甘露糖醇 | 12.5mg | 50 |
净化水 | 适量250μl | - |
I.崩解试验
Ia.培养皿中的崩解试验
此试验测量本发明的组合物在水介质中的预期崩解时间,这是其在唾液中的崩解时间的指示。
所有冻干物在湿滤纸上的崩解速率根据PCT申请WO2009002084第12页第129段中描述的方法确定,其中该试验在约25±2℃的温度进行。
Ib.安慰剂的口溶解时间(ODT)的测量
安慰剂冻干物在口腔中的溶解时间根据PCT申请WO2009002084第12页第132段中描述的方法确定,其中将所述冻干物置于健康成人的舌头上,然后在于舌头和上颚之间摩擦冻干物的同时测量其完全溶解所需的时间。平均ODT根据从5位健康成人获得的数据进行计算。
J.测试崩解时间(体外DT)的方法
此试验测量本发明的组合物在水介质中的崩解时间,其是它们在唾液中的崩解时间的指示。
设备:Electrolab,型号:ED2SAPO
程序:该方法按照USP31-NF26(通用章节,<701>崩解)和Ph Eur.1997(2.9.1.Disintegration of tablets and capsules(片剂和胶囊的崩解))进行。水被填充到大口杯中并使用水浴保持在37℃±0.5℃。将冻干物置于由直径为约0.5mm(±0.05mm)和长度为约15mm的铜线或不锈钢制成的沉头(sinker)中。然后将冻干物放入篮架(basket rack)组合件的篮中并启动仪器。崩解时间以秒计。
K.测试抗拉强度的方法
设备:Engineering Systems(NOTTM)Ltd,型号:5kN试验机
程序:将用于确定抗拉强度的方法输入仪器。将参数试验速度(15mm/min)、断裂类型、单位(牛顿,[N])、断裂百分比(80%)、下限(0.1)、以及支撑边缘之间的距离(4.5-6mm)设置到仪器中。使用10kg的测力元件(load cell)并利用下式计算抗拉强度:
N/mm2=3x平均值(N)x两个支撑轴之间的距离(mm)2x(厚度(mm))2x(直径(mm))
厚度和直径利用游标卡尺确定。
发现商购获得的Nimulid-MD(通过传统压缩技术制备的尼美舒利(Nimesulide)的口分散片剂)的抗拉强度为1.14N/mm2。
L.溶出方法
此试验测量在水介质中活性成分从本发明的组合物的溶出度(%),其是活性成分从组合物的释放速率的指示。
程序:含有活性成分的冻干物的溶出时间测量如下:该方法依照USP32-NF27(通用章节,<711>溶出)进行。基于组合物中的活性成分来选择溶出介质(0.1N HCl,磷酸盐缓冲液pH6.8,乙酸盐缓冲液pH4.5,或水中的0.5%SLS)。基于组合物中的活性成分以适当介质体积(500mL或900mL)填充溶出杯(dissolution bowl)并且使用水浴将介质的温度保持在37℃±0.5℃。使用的设备是II型USP(桨(Paddle))并根据试验程序设置在所需的rpm(50rpm)。根据试验程序中限定的时间点(5min、10min、15min和30min)收回样品。根据试验程序通过色谱法或通过UV来分析样品并计算%释放。
根据实施例1至19、以及比较例20至30制备的冻干物的崩解速率、ODT、体外DT、抗拉强度和溶出数据提供在表1中。
表1
NA–不适用于第3栏,因为口腔溶解时间仅对安慰剂冻干物进行测量。
NA–不适用于第6栏,因为溶出时间仅对含有药物的冻干物进行测量。
Claims (30)
1.一种药物组合物,所述药物组合物包含携带药学活性成分的开放式基质网络,其中所述开放式基质网络包含果聚糖和菊糖。
2.一种药物组合物,所述药物组合物包含携带药学活性成分的基质,所述基质在接触水介质或唾液后快速崩解,所述基质包含果聚糖和菊糖。
3.根据权利要求1-2中任一项的药物组合物,其中所述基质还包含甘露糖醇。
4.根据权利要求1-2中任一项的药物组合物,其中所述基质还包含海藻糖。
5.根据权利要求1-2中任一项的药物组合物,其中所述基质还包含棉子糖。
6.根据权利要求1-2中任一项的药物组合物,其中所述组合物的至少80%在30秒内溶解于水介质或唾液。
7.根据权利要求6的药物组合物,其中所述组合物的至少80%在10秒内溶解于水介质或唾液。
8.根据权利要求1或2的药物组合物,所述组合物具有约0.05-1.6N/mm2的抗拉强度和使得所述组合物的至少80%在30秒内溶解于水介质或唾液的快速溶出速率。
9.根据权利要求8的药物组合物,其中所述组合物在10秒内溶解于水介质或唾液。
10.根据权利要求1-9中任一项的药物组合物,其为口服剂型。
11.根据权利要求10的药物组合物,其适用于舌下给药。
12.根据权利要求1-11中任一项的药物组合物,其可通过从液体制剂升华溶剂获得,所述液体制剂包含在溶剂中的所述活性成分和果聚糖和菊糖。
13.根据权利要求12的药物组合物,其中所述升华通过冷冻干燥所述制剂进行。
14.根据权利要求1-13中任一项的药物组合物,其中所述活性成分是醋酸去氨加压素。
15.根据权利要求1-13中任一项的药物组合物,其中所述活性成分是氯雷他定。
16.根据权利要求1-13中任一项的药物组合物,其中所述活性成分是法莫替丁。
17.根据权利要求1-13中任一项的药物组合物,其中所述活性成分是孟鲁司特钠。
18.根据权利要求1-13中任一项的药物组合物,其中所述活性成分是昂丹司琼。
19.一种用于制备药物组合物的方法,所述方法包括从液体制剂升华溶剂,所述液体制剂包含在所述溶剂中的药学活性成分和果聚糖和菊糖。
20.根据权利要求19的方法,所述方法包括:(a)将单位剂量量的所述液体制剂引入到开放式泡罩包装的凹陷中;以及(b)升华所述制剂以在所述凹陷内获得固体单位剂型。
21.根据权利要求20的方法,其中所述升华通过冷冻干燥所述制剂进行。
22.根据权利要求21的方法,其中所述溶剂是水。
23.根据权利要求19-22中任一项的方法,其中所述活性成分是去氨加压素。
24.根据权利要求19-22中任一项的方法,其中所述活性成分是氯雷他定。
25.根据权利要求19-22中任一项的方法,其中所述活性成分是法莫替丁。
26.根据权利要求19-22中任一项的方法,其中所述活性成分是孟鲁司特钠。
27.根据权利要求19-22中任一项的方法,其中所述活性成分是昂丹司琼。
28.一种用于制备药物组合物的方法,所述方法包括:
(a)制备包含在溶剂中的果聚糖、菊糖和活性成分的溶液;
(b)冷冻所述溶液;
(c)从所述冷冻的溶液升华所述溶剂,
其中如此获得的所述药物组合物在接触水溶液或唾液后30秒内崩解。
29.根据权利要求28的方法,其在接触水溶液或唾液后10秒内崩解。
30.根据权利要求28-29的方法,其中所述组合物是根据权利要求1-18中任一项的组合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2683DE2011 | 2011-09-16 | ||
IN2683/DEL/2011 | 2011-09-16 | ||
PCT/EP2012/067507 WO2013037708A1 (en) | 2011-09-16 | 2012-09-07 | A fast dissolving pharmaceutical composition |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103781467A true CN103781467A (zh) | 2014-05-07 |
CN103781467B CN103781467B (zh) | 2016-08-31 |
Family
ID=46845743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280043356.2A Active CN103781467B (zh) | 2011-09-16 | 2012-09-07 | 一种快速溶解药物组合物 |
Country Status (17)
Country | Link |
---|---|
US (2) | US9731018B2 (zh) |
EP (1) | EP2755632A1 (zh) |
JP (1) | JP6174585B2 (zh) |
KR (1) | KR20140061438A (zh) |
CN (1) | CN103781467B (zh) |
AR (1) | AR087871A1 (zh) |
AU (1) | AU2012307530B2 (zh) |
BR (1) | BR112014005134A2 (zh) |
CA (1) | CA2848785A1 (zh) |
IL (1) | IL230861A (zh) |
MX (1) | MX345674B (zh) |
NZ (1) | NZ620897A (zh) |
RU (1) | RU2633640C2 (zh) |
SA (1) | SA112330855B1 (zh) |
TW (1) | TWI537010B (zh) |
WO (1) | WO2013037708A1 (zh) |
ZA (1) | ZA201401447B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114652689A (zh) * | 2022-03-02 | 2022-06-24 | 河北菲瑞生物技术有限公司 | 一种他达拉非冻干闪释片及制备工艺 |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3112B1 (ar) | 2010-03-29 | 2017-09-20 | Ferring Bv | تركيبة دوائية سريعة التحلل |
LT2714712T (lt) | 2011-06-01 | 2016-11-25 | Estetra S.P.R.L. | Estetrolio tarpinių junginių gamybos būdas |
US11053274B2 (en) | 2011-06-01 | 2021-07-06 | Estetra S.P.R.L. | Process for the production of estetrol intermediates |
EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
WO2015063602A1 (en) | 2013-10-29 | 2015-05-07 | Ferring B.V. | Desmopressin and blood glucose |
US9717684B2 (en) | 2014-04-25 | 2017-08-01 | R.P. Scherer Technologies, Llc | Stable montelukast solution |
PL3310346T3 (pl) | 2015-06-18 | 2021-10-25 | Estetra Sprl | Dyspergowalna w ustach tabletka zawierająca estetrol |
ES2877186T3 (es) | 2015-06-18 | 2021-11-16 | Estetra Sprl | Comprimido orodispersable que contiene estetrol |
TN2017000499A1 (en) | 2015-06-18 | 2019-04-12 | Mithra Pharmaceuticals S A | Orodispersible dosage unit containing an estetrol component |
US11147771B2 (en) | 2015-06-18 | 2021-10-19 | Estetra Sprl | Orodispersible dosage unit containing an estetrol component |
US20200046729A1 (en) * | 2016-08-05 | 2020-02-13 | Estetra Sprl | Methods using combined oral contraceptive compositions with reduced cardiovascular effects |
KR20220144885A (ko) | 2016-08-05 | 2022-10-27 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
BR112019010949A2 (pt) | 2017-01-11 | 2019-10-01 | Ferring Bv | composição farmacêutica de desintegração rápida |
TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1428526A1 (en) * | 2002-12-13 | 2004-06-16 | Rijksuniversiteit Groningen | Formulation for fast dissolution of lipophilic compounds |
WO2011120904A2 (en) * | 2010-03-29 | 2011-10-06 | Ferring B.V. | A fast dissolving pharmaceutical composition |
WO2011120903A2 (en) * | 2010-03-29 | 2011-10-06 | Ferring B.V. | A fast dissolving pharmaceutical composition |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
AU4052997A (en) | 1996-07-19 | 1998-02-10 | Clarke-Garegg, Margaret A. | Levan derivatives, their preparation, composition and applications including medical and food applications |
AU1827799A (en) | 1997-12-15 | 1999-07-05 | Axia Therapeutics, Inc. | Oral delivery formulation |
EP0958825A1 (en) | 1998-05-18 | 1999-11-24 | Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) | Synergistic composition of a non-digestible carbohydrate and an anti-cancer drug for use in the treatment of cancer |
SE9803871D0 (sv) | 1998-11-11 | 1998-11-11 | Pharmacia & Upjohn Ab | Therapeutic method and formulation |
WO2000025754A2 (en) | 1998-11-04 | 2000-05-11 | Mcneil-Ppc, Inc. | Solid oral dosage forms containing alginic acid and famotidine |
GB9901819D0 (en) | 1999-01-27 | 1999-03-17 | Scherer Corp R P | Pharmaceutical compositions |
GB9908014D0 (en) | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
NL1012300C2 (nl) * | 1999-06-11 | 2000-12-12 | Rijksuniversiteit | Stabilisator voor farmaca. |
CA2380449A1 (en) | 1999-08-17 | 2001-02-22 | Novartis Consumer Health S.A. | Rapidly dissolving dosage form and process for making same |
FR2803765B1 (fr) | 2000-01-14 | 2002-04-05 | Babolat Vs | Raquette de badminton |
US6815435B2 (en) | 2000-07-13 | 2004-11-09 | Daiichi Pharmaceutical Co., Ltd. | Pharmaceutical compositions containing DDS compounds |
IT1319664B1 (it) | 2000-11-17 | 2003-10-23 | Pharma Biotech Ltd | Addotti di antibatterici chinolonici con polimeri polisaccaridicinaturali. |
US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
MY148466A (en) | 2001-10-26 | 2013-04-30 | Merck Frosst Canada Ltd | Granule formulation |
EP1468036B1 (en) * | 2002-01-14 | 2008-10-08 | The General Hospital Corporation | Biodegradable polyketal polymers and methods for their formation and use |
CA2480270A1 (en) | 2002-04-03 | 2003-10-09 | Solvay Pharmaceuticals B.V. | Stabilized natural cannabinoid formulation |
GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
DE60307082D1 (de) | 2002-05-07 | 2006-09-07 | Ferring Bv | In der mundhöhle dispergierbare phamarzeutische zusammensetzung mit desmopressin |
US20040096569A1 (en) | 2002-11-15 | 2004-05-20 | Barkalow David G. | Edible film products and methods of making same |
US8012505B2 (en) | 2003-02-28 | 2011-09-06 | Alk-Abello A/S | Dosage form having a saccharide matrix |
CA2516291C (en) | 2003-02-28 | 2012-02-14 | Alk-Abello A/S | Dosage form having a saccharide matrix |
EP1514553B1 (en) | 2003-09-05 | 2008-02-27 | Chung, Myung-jun | Lactic acid bacteria powder double-coated using protein and polysaccharide and method preparing the same and a dosage form thereof |
CN100366294C (zh) | 2004-04-30 | 2008-02-06 | 量子高科(北京)研究院有限公司 | 一种口腔速溶制剂及其生产方法 |
BRPI0519212A2 (pt) | 2004-12-23 | 2009-01-06 | Mcneil Ppc Inc | composiÇÕes farmacÊuticas de desintegraÇço oral contendo agentes de manifestaÇço sensorial |
US20070042023A1 (en) | 2005-08-22 | 2007-02-22 | National Starch And Chemical Investment Holding Corporation | Dissolvable film |
US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
WO2007070660A2 (en) | 2005-12-13 | 2007-06-21 | President And Fellows Of Harvard College | Scaffolds for cell transplantation |
TW200817049A (en) | 2006-06-05 | 2008-04-16 | Verus Pharmaceuticals Inc | Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms |
CN101686942B (zh) | 2007-06-27 | 2012-09-26 | 韩美药品株式会社 | 用于快速制备用于口服的崩解剂的方法及其产品 |
KR100930427B1 (ko) | 2008-01-25 | 2009-12-08 | 정명준 | 3중 코팅 유산균의 제조방법 및 나노 입자 코팅 방법, 그방법으로 제조된 3중 코팅 유산균 및 이를 포함하는 제품 |
US8623401B2 (en) | 2008-03-27 | 2014-01-07 | Fenwafe Inc. | Wafer formulation |
-
2012
- 2012-09-07 US US14/343,285 patent/US9731018B2/en active Active
- 2012-09-07 RU RU2014105585A patent/RU2633640C2/ru not_active IP Right Cessation
- 2012-09-07 NZ NZ620897A patent/NZ620897A/en not_active IP Right Cessation
- 2012-09-07 EP EP12758830.9A patent/EP2755632A1/en not_active Withdrawn
- 2012-09-07 WO PCT/EP2012/067507 patent/WO2013037708A1/en active Application Filing
- 2012-09-07 JP JP2014530163A patent/JP6174585B2/ja active Active
- 2012-09-07 AU AU2012307530A patent/AU2012307530B2/en not_active Ceased
- 2012-09-07 KR KR1020147006141A patent/KR20140061438A/ko not_active Application Discontinuation
- 2012-09-07 MX MX2014002664A patent/MX345674B/es active IP Right Grant
- 2012-09-07 CA CA2848785A patent/CA2848785A1/en not_active Abandoned
- 2012-09-07 BR BR112014005134A patent/BR112014005134A2/pt not_active Application Discontinuation
- 2012-09-07 CN CN201280043356.2A patent/CN103781467B/zh active Active
- 2012-09-13 TW TW101133462A patent/TWI537010B/zh not_active IP Right Cessation
- 2012-09-14 AR ARP120103389A patent/AR087871A1/es unknown
- 2012-09-16 SA SA112330855A patent/SA112330855B1/ar unknown
-
2014
- 2014-02-06 IL IL230861A patent/IL230861A/en not_active IP Right Cessation
- 2014-02-25 ZA ZA2014/01447A patent/ZA201401447B/en unknown
-
2017
- 2017-07-10 US US15/644,933 patent/US20170304456A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1428526A1 (en) * | 2002-12-13 | 2004-06-16 | Rijksuniversiteit Groningen | Formulation for fast dissolution of lipophilic compounds |
WO2011120904A2 (en) * | 2010-03-29 | 2011-10-06 | Ferring B.V. | A fast dissolving pharmaceutical composition |
WO2011120903A2 (en) * | 2010-03-29 | 2011-10-06 | Ferring B.V. | A fast dissolving pharmaceutical composition |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114652689A (zh) * | 2022-03-02 | 2022-06-24 | 河北菲瑞生物技术有限公司 | 一种他达拉非冻干闪释片及制备工艺 |
Also Published As
Publication number | Publication date |
---|---|
AR087871A1 (es) | 2014-04-23 |
KR20140061438A (ko) | 2014-05-21 |
IL230861A (en) | 2017-03-30 |
RU2014105585A (ru) | 2015-11-10 |
BR112014005134A2 (pt) | 2017-04-18 |
JP6174585B2 (ja) | 2017-08-02 |
CA2848785A1 (en) | 2013-03-21 |
ZA201401447B (en) | 2014-12-23 |
MX345674B (es) | 2017-02-10 |
CN103781467B (zh) | 2016-08-31 |
AU2012307530A1 (en) | 2014-03-20 |
MX2014002664A (es) | 2014-04-25 |
NZ620897A (en) | 2016-07-29 |
TW201317009A (zh) | 2013-05-01 |
JP2014526483A (ja) | 2014-10-06 |
EP2755632A1 (en) | 2014-07-23 |
US20150045300A1 (en) | 2015-02-12 |
WO2013037708A1 (en) | 2013-03-21 |
IL230861A0 (en) | 2014-03-31 |
RU2633640C2 (ru) | 2017-10-16 |
SA112330855B1 (ar) | 2015-08-19 |
US20170304456A1 (en) | 2017-10-26 |
AU2012307530B2 (en) | 2016-12-08 |
US9731018B2 (en) | 2017-08-15 |
TWI537010B (zh) | 2016-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103781467B (zh) | 一种快速溶解药物组合物 | |
CN102834091B (zh) | 一种快速溶解药物组合物 | |
US10512695B2 (en) | Fast dissolving pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |